

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

#5

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (51) International Patent Classification ⁶: A61K 38/14 | A1 | (11) International Publication Number: WO 95/10296 (43) International Publication Date: 20 April 1995 (20.04.95) |
| (21) International Application Number: PCT/US94/11370 (22) International Filing Date: 4 October 1994 (04.10.94) (30) Priority Data: 08/134,958 12 October 1993 (12.10.93) US (71) Applicant: GLYCOMED INCORPORATED [US/US]; 860 Atlantic Avenue, Alameda, CA 94501 (US). (72) Inventors: RAO, Narasinga; 38 Ulster Place, Alameda, CA 94501 (US). MELDAL, Morten; Malov Hovedgade 109, DK-2760 Malov (DK). BOCK, Klaus; Skovvaenget 10C, DK-2970 Horsholm (DK). HINDSGAUL, Ole; 9330 81 Avenue, Edmonton, Alberta T6C 0X3 (CA). (74) Agent: GIOTTA, Gregory, J.; Glycomed Incorporated, 860 Atlantic Avenue, Alameda, CA 94501 (US). | | (21) Designated States: AT, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> |
| (54) Title: A LIBRARY OF GLYCO-PEPTIDES USEFUL FOR IDENTIFICATION OF CELL ADHESION INHIBITORS (57) Abstract The subject invention provides for a novel bio-oligomer library. The glyco-peptides of the subject invention are glyco-peptides. The instant invention also provides methods to identify glyco-peptides from the library that demonstrate desired characteristics such as inhibiting cell adhesion. The invention also provides for effector molecules useful in inhibiting cell adhesion. | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | |
|----|--------------------------|----|---------------------------------------|----|--------------------------|
| AT | Austria | GB | United Kingdom | MR | Mauritania |
| AU | Australia | GE | Georgia | MW | Malawi |
| BB | Barbados | GN | Guinea | NE | Niger |
| BE | Belgium | GR | Greece | NL | Netherlands |
| BF | Burkina Faso | HU | Hungary | NO | Norway |
| BG | Bulgaria | IE | Ireland | NZ | New Zealand |
| BJ | Benin | IT | Italy | PL | Poland |
| BR | Brazil | JP | Japan | PT | Portugal |
| BY | Belarus | KE | Kenya | RO | Romania |
| CA | Canada | KG | Kyrgyzstan | RU | Russian Federation |
| CF | Central African Republic | KP | Democratic People's Republic of Korea | SD | Sudan |
| CG | Congo | KR | Republic of Korea | SE | Sweden |
| CH | Switzerland | KZ | Kazakhstan | SI | Slovenia |
| CI | Côte d'Ivoire | LI | Liechtenstein | SK | Slovakia |
| CM | Cameroon | LR | Liberia | SN | Senegal |
| CN | China | LU | Luxembourg | TD | Chad |
| CS | Czechoslovakia | LV | Latvia | TG | Togo |
| CZ | Czech Republic | MC | Monaco | TJ | Tajikistan |
| DE | Germany | MD | Republic of Moldova | TT | Trinidad and Tobago |
| DK | Denmark | MG | Madagascar | UA | Ukraine |
| ES | Spain | ML | Mali | US | United States of America |
| FI | Finland | MN | Mongolia | UZ | Uzbekistan |
| FR | France | | | VN | Viet Nam |
| GA | Gabon | | | | |

A LIBRARY OF GLYCO-PEPTIDES USEFUL FOR
IDENTIFICATION OF CELL ADHESION INHIBITORS

Field of the Invention

5 The present invention relates generally to a collection or library of bio-oligomers. The bio-oligomer of this invention is a glyco-peptide. The invention relates to the use of glyco-peptides to identify lectins or carbohydrate binding proteins. The invention also relates to the use of glyco-peptides to identify and characterize inhibitors of cell adhesion. More specifically, the invention relates to the use of glyco-peptides to identify and characterize
10 selectin binding inhibitors.

Background of the Invention

Recognition and binding of ligands regulate almost all biological processes such as immune recognition, cell signalling and communication, transcription and translation,
15 intercellular signaling and enzyme catalysis. There is a longstanding interest in the art to identify molecules which act as agonists or which can agonize or antagonize the activities of peptide ligands such as hormones, growth factors and neurotransmitters.

Scientists have long hypothesized about the role of carbohydrates in intracellular signaling and communication and, in particular, cellular adhesion. Cellular adhesion is a
20 basic biomolecular process involved in many aspects of development including: initiation of fertilization, induction of differentiation, growth control and cell migration (Frazier *et al.* (1979) Ann. Rev. Biochem. 48:491). Compounds that alter cell-cell adhesive interactions have many potential medical applications including use as anti-infectives, anti-inflammatories, contraceptives, etc. Recently, a new group of cell surface lectins
25 involved in cell adhesion, the LEC-CAMs or selectins, have been identified. The selection family of receptors have been implicated in the initial interactions between leukocytes and vascular endothelia leading to lymphocyte homing, platelet binding and neutrophil extravasation (Hallman *et al.*, (1991) Biochem. Biophys. Res. Commun. 174:236-243; Lawrence *et al.*, (1990) Cell 65:859-873; Luscinskas, *et al.*, (1989) J. Immunol.
30 142:2257-2263). The selectin family of receptors includes L-selectin, involved in

lymphocyte homing to peripheral lymph nodes; P-selectin, which participates in adhesion of activated platelets and E-selectin which appears to facilitate T-cell infiltration at sites of cutaneous inflammation. (Picker et al., (1991) Nature 349:796-799; Shimizu et al. (1991) Nature 349:799-802).

5 A number of selectins bind to oligosaccharides terminating in the Sialyl Lewis X (SLe^x) or Sialyl Lewis A sequence. Although there is disagreement as to whether Lewis A (Le-a) or non-sialylated Le^x also bind, it is fairly well established that fucose is required for binding. This suggests that the combining site of the selectin protein must make a critical interaction with the fucose residue. Therefore, the probability of success in designing an
10 inhibitor of this interaction might be greatly increased if a fucose moiety was incorporated into the structure. This ligand-selectin interaction might be further strengthened by the addition of peptide based molecular structure (scaffolding) which might interact favorably with protein structure in or near the selectin binding site (not at all necessarily mimicking the binding of SLe^x and not necessarily binding in the same place). If this peptide
15 scaffolding were designed to interact favorably with the selectin, then an inhibitor could be conceived that might possess the same specificity elements as SLe^x and possibly bind even tighter.

 The development of pharmaceutical agents keyed to receptor binding sites, however, has been greatly hampered by the difficulty in determining the structure of the peptide
20 ligands. The sheer number and variety of such peptide sequences has made this an unattainable goal on any basis except by laboriously isolating a specific complex, identifying the structure of the ligand (potential drug). The problem is further complicated by the fact that often the ligand consists of amino acid residues that are not contiguous in the primary sequence.

25 Recently, there have been several reports on the preparation of peptide libraries and their use in identifying peptide ligands that can bind to acceptors. One approach uses recombinant bacteriophage to produce large libraries. Using the "phage method" (Scott and Smith, 1990, Science 249:386-390; Cwirla, et al., 1990, Proc. Natl. Acad. Sci., 87:6378-6382; Devlin et al., 1990, Science, 249:404-406), very large libraries can be
30 constructed. The genetic code and the biological system, however, imposes severe inherent limitations on the versatility and diversity of the library. A second approach uses primarily

chemical methods, of which the Geysen method (Geysen et al., 1986, Molecular Immunology 23:709-715; Geysen et al. 1987, J. Immunologic Methods 102:259-274) and the recent method of Fodor et al: (1991, Science 251, 767-773) are examples. The methodology of Geysen et al. provides for a limited number of peptides (10^3 - 10^4) that can be synthesized
5 on polyethylene pins in a few days. The method of Fodor et al. utilizes a "light-directed spatially addressable parallel chemical synthesis" technique. This technique is also limited by the relative lack of development of photochemical peptide synthesis methods.

Large scale parallel concurrent peptide synthesis techniques have also been developed. Houghton reported synthesizing hundreds of analogous peptides simultaneously
10 in polypropylene mesh packets (tea bag method) (Houghton, 1985, Proc. Natl. Acad. Sci. 82:5131-5135). Berg et al. (1989, J. Am. Chem. Sci. 111:8024-8026) reported a novel polystyrene-grafted polyethylene film support that is suitable for peptide synthesis in parallel fashion. Both techniques used standard Boc amino acid resin with the standard deprotecting, neutralization, coupling and wash protocols of the original solid phase
15 procedure of Merrifield (1963, J. Am. Chem. Sci. 85:2149-2154).

A parallel multiple column peptide synthesizer which operates exclusively by the distribution of solutions into a Teflon block containing 96 column reactors arranged in an Elisa-type arrangement has been described (Holm, A., et al., 1989 Peptides 1988 (G. Jung and E. Bayer, eds.) Walter de Gruyter, Amsterdam). The preparation of building blocks
20 N^{α} -Fmoc-Ser(Ac_3 - α -D-GalpNAc)-OPfp and N^{α} Fmoc-Thr(Ac_3 - α -D-GalpNAc)-OPfp and their application in a simultaneous multiple-column solid-phase synthesis of multiple O-glycopeptides has been described (Peters et al., 1992, J. Chem. Soc. Perkin Trans 1:1163-1171).

An apparatus for the parallel synthesis of a large number of peptides having
25 overlapping amino acid sequences and constituting part of a longer peptide chain has been developed (PCT/DK89/00206).

A random bio-oligomer library, consisting of all possible combinations of monomer peptide, oligonucleotide or chimeric peptide-oligonucleotide constructs has been proposed (PCT/US91/04666). The library is screened by introducing an acceptor or substrate
30 molecule of interest to the library such that the acceptor molecule recognizes and binds to one or more solid phase support/bio-oligomer species within the library. The solid phase

support/bio-oligomer combination that exhibits the desired property is isolated and the bio-oligomer sequenced for specific identification.


Although useful, none of the procedures developed to date combine the flexibility of a random collection of bio-oligomers or a bio-oligomer library with the specificity of potentially critical peptide modifications. In particular, none of the procedures thus far developed utilize the specificity offered by glyco-peptides.

There is thus a need in the art for a collection or a library of peptide sequences to which a carbohydrate is covalently attached for the isolation of specific lectins or carbohydrate binding proteins including selectin binding inhibitors. Such a library or collection of peptides would combine the flexibility and ease of the screening of a random peptide library, with the specificity offered by the attachment of peptide scaffolding to a critical carbohydrate residue.

Summary of the Invention

The present invention is directed toward a collection or a library of glyco-peptide templates as well as to methods of use of the glyco-peptides to identify specific biological acceptor molecules.

One aspect of the current invention is a glyco-peptide having the structure:



wherein A is an amino acid, preferably an amino acid selected from the group consisting of serine, threonine, tyrosine, hydroxyproline, homoserine and hydroxylysine or asparagine and glutamine;

wherein R is a carbohydrate, preferably a carbohydrate selected from the group consisting of fucose, glucose, N-acetylglucosamine, galactose, arabinose, N-acetylgalactosamine and sialic acid;

In a preferred embodiment of glyco-peptide I, A is serine, R is O-glucosidically linked to said serine and the subunits of X_1 to X_{12} are selected from the group consisting of D and L alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, hydroxyproline, hydroxylysine and non-genetically

encoded amino acids and peptidomimetics.

X_1 may be a carboxylic acid residue, e.g. acetyl, benzoyl or formyl group. X_{12} may be an -OH or -NH₂ group. X_1 and X_{12} may also be peptides.

In yet another preferred embodiment of glyco-peptide I, R is selected from the group
5 consisting of α -L or α -D-fucose and β -L or β -D-fucose.

In yet another preferred embodiment, the glycopeptide (I) is attached to a solid phase support.

In a most preferred embodiment, glyco-peptide (I) of the present invention is selected from the group consisting of:

- 10 Ac-Ser(α -L-Fuc)-Asp-Asp-NH₂,
- Ac-Ser(α -L-Fuc)-Ser-Asp-NH₂,
- Ac-Ser(α -L-Fuc)-Phe-Asp-NH₂,
- Ac-Ser(α -L-Fuc)-Asn-Asp-NH₂,
- Ac-Ser(α -L-Fuc)-Leu-Asp-NH₂,
- 15 Ac-Ser(α -L-Fuc)-Pro-Asp-NH₂,
- Ac-Ser(β -L-Fuc)-Gly-Asp-NH₂,
- Ac-Ser(β -L-Fuc)-Asp-Asp-NH₂,
- Ac-Ser(β -L-Fuc)-Leu-Asp-NH₂,
- Ac-Ser(β -L-Fuc)-Asn-Asp-NH₂,
- 20 Ac-Ser(α -L-Fuc)-Ala-Asp-NH₂,
- Ac-Ser(β -L-Fuc)-Ala-Asp-NH₂,
- Ac-Ser(β -L-Fuc)-Ser-Asp-NH₂,
- Ac-Ser(β -L-Fuc)-Pro-Asp-NH₂,
- Ac-Ser(α -L-Fuc)-Arg-Asp-OH,
- 25 Ac-Ser(α -L-Fuc)-Phe-Asp-OH,
- Ac-Ser(α -L-Fuc)-Ser-Asp-OH,
- Ac-Ser(α -L-Fuc)-Asn-Asp-OH,
- Ac-Ser(α -L-Fuc)-Asp-Asp-OH,
- Ac-Ser(α -L-Fuc)-Leu-Asp-OH,
- 30 Ac-Ser(α -L-Fuc)-Gly-Asp-OH,
- Ac-Ser(α -L-Fuc)-Pro-Asp-OH,

- Ac-Ser(β -L-Fuc)-Arg-Asp-OH,
Ac-Ser(β -L-Fuc)-Phe-Asp-OH,
Ac-Ser(β -L-Fuc)-Ser-Asp-OH,
Ac-Ser(β -L-Fuc)-Asn-Asp-OH,
5 Ac-Ser(β -L-Fuc)-Asp-Asp-OH,
Ac-Ser(β -L-Fuc)-Leu-Asp-OH,
Ac-Ser(β -L-Fuc)-Gly-Asp-OH,
Ac-Ser(β -L-Fuc)-Pro-Asp-OH,
Ac-Ser(α -L-Fuc)-Arg-Gly-OH,
10 Ac-Ser(α -L-Fuc)-Phe-Gly-OH,
Ac-Ser(α -L-Fuc)-Ser-Gly-OH,
Ac-Ser(α -L-Fuc)-Asn-Gly-OH,
Ac-Ser(α -L-Fuc)-Asp-Gly-OH,
Ac-Ser(α -L-Fuc)-Leu-Gly-OH,
15 Ac-Ser(α -L-Fuc)-Gly-Gly-OH,
Ac-Ser(α -L-Fuc)-Pro-Gly-OH,
Ac-Ser(β -L-Fuc)-Arg-Gly-OH,
Ac-Ser(β -L-Fuc)-Phe-Gly-OH,
Ac-Ser(β -L-Fuc)-Ser-Gly-OH,
20 Ac-Ser(β -L-Fuc)-Asn-Gly-OH,
Ac-Ser(β -L-Fuc)-Asp-Gly-OH,
Ac-Ser(β -L-Fuc)-Leu-Gly-OH,
Ac-Ser(β -L-Fuc)-Gly-Gly-OH,
Ac-Ser(β -L-Fuc)-Pro-Gly-OH,
25 Ac-Ser(α -L-Fuc)-Arg-Glu-NH₂,
Ac-Ser(α -L-Fuc)-Phe-Glu-NH₂,
Ac-Ser(α -L-Fuc)-Ser-Glu-NH₂,
Ac-Ser(α -L-Fuc)-Asn-Glu-NH₂,
Ac-Ser(α -L-Fuc)-Asp-Glu-NH₂,
30 Ac-Ser(α -L-Fuc)-Leu-Glu-NH₂,
Ac-Ser(α -L-Fuc)-Gly-Glu-NH₂.

Ac-Ser(α -L-Fuc)-Pro-Glu-NH₂,
Ac-Ser(β -L-Fuc)-Arg-Glu-NH₂,
Ac-Ser(β -L-Fuc)-Phe-Glu-NH₂,
Ac-Ser(β -L-Fuc)-Ser-Glu-NH₂,
5 Ac-Ser(β -L-Fuc)-Asn-Glu-NH₂,
Ac-Ser(β -L-Fuc)-Asp-Glu-NH₂,
Ac-Ser(β -L-Fuc)-Leu-Glu-NH₂,
Ac-Ser(β -L-Fuc)-Gly-Glu-NH₂, and
Ac-Ser(β -L-Fuc)-Pro-Glu-NH₂.

10

Another aspect of the current invention involves a method (Method 1) for identifying a glyco-peptide ligand for an acceptor molecule. Method 1 consists of the steps of:

- (a) generating the glyco-peptide compound (I);
- (b) introducing to glyco-peptide compound (I) an acceptor molecule of interest
- 15 such that the acceptor molecule will recognize and bind to said glyco-peptide; and
- (c) isolating and defining a glyco-peptide that exhibits binding with the acceptor molecule.

In a preferred embodiment of Method 1, the acceptor molecule is selected from the group consisting of antibodies, lectins, receptors, viruses, bacteria, proteins, carbohydrates,

20 nucleic acids, lipids, drugs, metals and small molecules.

In a most preferred embodiment of Method 1, the acceptor molecule is a selectin protein.

Another aspect of the current invention involves a method (Method 2) for identifying a biologically active glyco-peptide ligand consisting of the steps of:

- 25 (a) generating glyco-peptide (I) which is attached to a solid phase support and in which the solid phase support is modified so that a portion of the glyco-peptide can be released;
- (b) releasing a portion of the glyco-peptide from the solid phase support/glyco-peptide combination in situ;
- 30 (c) detecting the biological activity of the released glyco-peptide that exhibits the specific biological activity of interest;

(d) isolating a solid phase support/glyco-peptide combination that exhibits the specific biological activity of interest; and

(e) determining the sequence of the glyco-peptide remaining in the solid phase support/glyco-peptide isolated in step (d).

5 In a preferred embodiment of Method 2 of the current invention, the solid phase support is modified to be acid-sensitive, base-sensitive, nucleophilic-sensitive, photosensitive, oxidation-sensitive, or reduction-sensitive.

In another preferred embodiment of Method 2 of the current invention, the in situ release of step (b) is affected by enzymatic cleavage, chemical cleavage or a
10 photochemical cleavage.

In yet another preferred embodiment of Method 2 of the current invention the detection of step (c) is of a biological activity selected from the group consisting of cytotoxicity, anti-tumor activity, anti-bacterial activity, anti-fungal activity, anti-viral activity, anti-parasite activity, growth factor activity, growth inhibitor activity,
15 hormone activity, neurotransmitter activity, immunomodulator activity, and anti-cell adhesion activity.

Another preferred embodiment of the instant invention concerns an anti-cell adhesion molecule, a therapeutic agent, a cytotoxic molecule, an anti-tumor molecule, an anti-microbial molecule, a growth factor agonist, a growth factor antagonist, a
20 hormone agonist, a hormone antagonist, and a cytotoxic molecule consisting of a glyco-peptide sequence determined according to Methods 1 and 2 of the current invention. The present invention further provides therapeutic and diagnostic agents comprising glycopeptide sequences determined according to the foregoing methods.

The present invention provides for the identification of carbohydrate binding
25 proteins or cellular adhesion inhibitors. Such inhibitors find use in numerous medical applications including use as anti-infectives, anti-inflammatories, contraceptives, etc.

Description of the Figures

Figures 1A-1E show a diagram of the synthesis of Fmoc-Ser(Ac₃-β-L-Fuc).
30 Figures 2A-2F show a diagram of the synthesis of Fmoc-Ser(Ac₃-α-L-Fuc).
Figure 3 shows a diagram of the interactions of SLeX and the SLeX

glyco-peptide mimic with the selectin binding site.

Figure 4 shows a diagram of glycotripeptides Ac-Ser(L-Fuc)-Ala-Asp-NH₂. The fucose can be in the α or β configuration.

Figure 5 shows the results from a competitive inhibition assay of L, E and P selectins with Ac-Ser(α -L-Fuc)-Ala-Asp-NH₂ (A) and Ac-Ser(β -L-Fuc)-Ala-Asp-NH₂ (B).

Figure 6 shows the results from a competitive inhibition assay of L, E and P selectins with Ac-Ser(α -L-Fuc)-Ala-Asp-NH₂ (A) and Ac-Ser(β -L-Fuc)-Ala-Asp-NH₂ (B).

Figure 7 shows the results from a competitive inhibition assay of P-selectin with: C: Ac-Ser-Phe-Asp-NH₂; D: Ac-Ser-Asn-Asp-NH₂; E: Ac-Ser(α -L-Fuc)-Gly-Asp-NH₂; F: Ac-Ser-Ser-Asp-NH₂ and G: Ac-Ser(β -L-Fuc)-Arg-Asp-NH₂ together with 2,3 SLex glycolipid.

Figure 8 shows the results from a competitive inhibition assay of L-selectin with: C: Ac-Ser-Phe-Asp-NH₂; D: Ac-Ser-Asn-Asp-NH₂; E: Ac-Ser(α -L-Fuc)-Gly-Asp-NH₂; F: Ac-Ser-Ser-Asp-NH₂ and H: Ac-Ser(α -L-Fuc)-Arg-Asp-NH₂ together with 2,3 SLex glycolipid.

Figure 9A is an NMR spectrum of Ac-Ser-Phe-Asp-NH₂.

Figure 9B is an NMR spectrum of Ac-Ser-Asn-Asp-NH₂.

Figure 10A is an NMR spectrum of Ac-Ser(α -L-Fuc)-Gly-Asp-NH₂.

Figure 10B is an NMR spectrum of Ac-Ser-Ser-Asp-NH₂.

Figure 11A is an NMR spectrum of Ac-Ser(β -L-Fuc)-Arg-Asp-NH₂.

Figure 11B is an NMR spectrum of Ac-Ser(α -L-Fuc)-Arg-Asp-NH₂.

Figure 12 is an NMR spectrum of Ac-Ser(α -L-Fuc)-Phe-Asp-NH₂.

Figure 13 is an NMR spectrum of Ac-Ser(α -L-Fuc)-Ser-Asp-NH₂.

Figure 14 is an NMR spectrum of Ac-Ser(α -L-Fuc)-Asn-Asp-NH₂.

Figure 15 is an NMR spectrum of Ac-Ser(α -L-Fuc)-Asp-Asp-NH₂.

Figure 16 is an NMR spectrum of Ac-Ser(α -L-Fuc)-Leu-Asp-NH₂.

Figure 17 is an NMR spectrum of Ac-Ser(α -L-Fuc)-Gly-Asp-NH₂.

Figure 18 is an NMR spectrum of Ac-Ser(α -L-Fuc)-Pro-Asp-NH₂.

Figure 19 is an NMR spectrum of Ac-Ser-Arg-Asp-NH₂.

Figure 20 is an NMR spectrum of Ac-Ser-Arg-Asp-NH₂.

Figure 21 is an NMR spectrum of Ac-Ser-Phe-Asp-NH₂.

Figure 22 is an NMR spectrum of Ac-Ser(β -L-Fuc)-Arg-Asp-NH₂.

Figure 23 is an NMR spectrum of Ac-Ser(β -L-Fuc)-Phe-Asp-NH₂.

5 Figure 24 is an NMR spectrum of Ac-Ser(β -L-Fuc)-Ser-Asp-NH₂.

Figure 25 is an NMR spectrum of Ac-Ser(β -L-Fuc)-Asn-Asp-NH₂.

Figure 26 is an NMR spectrum of Ac-Ser(β -L-Fuc)-Asp-Asp-NH₂.

Figure 27 is an NMR spectrum of Ac-Ser(β -L-Fuc)-Leu-Asp-NH₂.

Figure 28 is an NMR spectrum of Ac-Ser(β -L-Fuc)-Gly-Asp-NH₂.

10 Figure 29 is an NMR spectrum of Ac-Ser(β -L-Fuc)-Pro-Asp-NH₂.

Figure 30 is an NMR spectrum of Ac-Ser-Ser-Asp-NH₂.

Figure 31 is an NMR spectrum of Ac-Ser-Asn-Asp-NH₂.

Description of the Preferred Embodiments

15 Definitions

The term "library" as used herein refers to a collection of bio-oligomers.

The term "bio-oligomer" refers to a polymer of less than about 100 subunits. A "bio-oligomer" of the instant invention may be a glyco-peptide; i.e., a chimera comprised of amino acid and carbohydrate subunits.


20 The term "lectin" as used herein refers to proteins that recognize specific carbohydrate residues and bind to cell surface glyco-proteins or glyco-lipids.

The term "peptidomimetic" as used herein refers to a molecule that structurally and chemically resembles a peptide of two or more amino acids

The term "cell adhesion" as used herein refers to the initial contacts between two cells.

25 The term "selectin" as used herein refers to a family of cell surface receptors involved in the initial interactions between leukocytes and vascular endothelia leading to lymphocyte homing, platelet binding and neutrophil extravasation.

The term "fucose" as defined herein refers to compounds having the formula:



Detailed Description of the Invention

10 Methods of Generating a Collection of Glyco-Peptides

Detailed methods of synthesis of the fucose-serine building blocks are provided in the example section below.

Fucose-serine building blocks are prepared using fluoren-9-yl-methoxycarbonyl (Fmoc) protection of amino groups, pentafluorophenol-ester (Pfp-ester) activation for
 15 coupling, trifluoroacetic acid (TFA) sensitive side-chain protection and monitoring of coupling reactions colorimetrically using 3,4-dihydro-3-hydroxy-4-oxo-1,2,3- benzotriazine (Dhbt-OH) as an indicator.

Glyco-peptides are synthesized from the fucose-serine building blocks by activating with O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluroniumtetrafluoroborate (TBTU) and
 20 4-ethylmorpholine, removing the Fmoc group with 20% piperidine or 50% morpholine in dimethylformamide (DMF), coupling the first amino acid as Dhbt ester to the linker, and introducing subsequent amino acids into the peptide chain as Dhbt-esters. The progress of the peptide bond formation is monitored by the decrease in coloration of the solid support. After attachment of the last amino acid and Fmoc removal, the terminal amino groups are
 25 acetylated with acetic anhydride in DMF. The glycopeptides are cleaved off the resin by treatment with 95% TFA with concurrent removal of the O-tBu groups. Deacetylation of the carbohydrate unit is performed with sodium methoxide in methanol or hydrazine in 50% methanol/water. Crude products are purified by preparative reverse phase HPLC. Compounds are characterized by 1D and 2D-1H-NMR.

30 A collection or library comprising glyco-peptides, oligonucleotides, or glyco-peptide-oligonucleotide chimeras may be generated by a method comprising repeating

the step of:

- (a) providing at least two aliquots of a solid phase support for the random subunit sequences;
- (b) separately introducing a set of subunits to the aliquots of the solid phase support;
- 5 (c) completely coupling the subunits to substantially all of the sites of the solid phase support to form a solid phase support/new subunit combination;
- (d) assessing the completeness of coupling and, if necessary, forcing the reaction to completeness;
- (e) thoroughly mixing the aliquots of the solid phase support/new subunit
- 10 combination; and, after repeating steps (a)-(e) the desired number of times, a final step of (f) removing the protecting groups such that the bio-oligomer remains linked to the solid phase support.

Glyco-peptide Libraries

- 15 In a particular embodiment, the bio-oligomer collection or library may comprise peptides. The term "peptide" is used in its broadest sense to refer to a compound of two or more subunit amino acids, amino acid analogs or peptidomimetics. The subunits may be linked by peptide bonds. In another embodiment, the subunit may be linked by other bonds, e.g., ester, ether, etc. As used herein the term "amino acid" refers to either natural and/or
- 20 unnatural or synthetic amino acids including glycine and both the D or L optical isomers, and amino acid analogs and peptidomimetics. A peptide of three or more amino acids is commonly called an oligopeptide if the peptide chain is short. If the peptide chain is long the peptide is commonly called a polypeptide or a protein.

- The present invention is based on synthetic peptide chemistry and does not rely on
- 25 any living system for amplification or screening. Peptide libraries can include unnatural amino acids. Thus, peptides of the invention may comprise D-amino acids, a combination of D- and L-amino acids, and various "designer" amino acids (e.g., β -methyl amino acids, C $^{\alpha}$ -methyl amino acids, and N $^{\alpha}$ -methyl amino acids, etc.) to convey special properties to peptides in the library. Additionally, by assigning specific amino acids at specific coupling
- 30 steps, peptide libraries with α -helices, β turns, β sheets, γ -turns, and cyclic peptides can be generated.

The library of peptides of the invention includes all possible combinations of amino acids of which the peptides are composed. Using as an example a dipeptide made up of the two amino acids glycine and proline, there are four possible combinations: glycine-glycine, glycine-proline, proline-glycine, and proline-proline, and the random library will contain all
5 four combinations.

A set of first amino acids is separately introduced to each aliquot. Generally, the amino acids used for peptide synthesis are the base-labile N^α -amino protected 9-fluorenylmethoxycarbonyl (Fmoc) amino acids first described by Carpino and Han (1972, J. Org. Chem., 37:3403-3409). The method of the present invention may also be used with the
10 Boc-amino acids (N^α -amino protected N^α -t-butyloxycarbonyl). Both Fmoc and Boc N^α -amino protected amino acids can be obtained from Fluka, Bachem, Advanced Chemtech, Sigma, Cambridge Research Biochemical, Bachem, or Peninsula Labs or other chemical companies familiar to those who practice this art. In addition, the method of the invention can be used with other N^α -protecting groups that are familiar to those skilled in this art.
15 Continuing with the dipeptide example described above, the first set of amino acids introduced would comprise glycine and proline; each aliquot receives either an N^α -Fmoc-glycine or an N^α -Fmoc-proline.

After introduction, the set of first amino acids is completely coupled to substantially all the sites of the solid phase supports. As used herein, complete coupling means that the
20 coupling reaction is driven to completion irrespective of the differences in the coupling rates of individual amino acids. In addition, the amino acids are coupled to substantially all available coupling sites on the solid phase support so that each particle of the solid support will contain essentially only one species of peptide. Complete coupling will result in solid phase support/first amino acid combinations. Using the dipeptide described above as an
25 example, the completion of the coupling will yield a bead-glycine combination and a bead-proline combination.

A spectrophotometric technique has been described for monitoring the course of acylation reactions in solid phase peptide synthesis using fluorenylmethoxycarbonyl amino acid 3,4-dihydro-4-oxo-1,2,3-benzotriazin-3-yl esters. The procedure has allowed
30 construction of a fully automated peptide synthesizing system in which acylation and deprotection steps may be checked automatically for completion before proceeding to the

next amino acid residue. (Cameron, et al., J. Chem. Soc. Perkin Trans. 1:2895-901 (1988))

In order to couple an amino acid to a growing synthetic chain, the carboxyl group of the blocked amino acid must be activated. Many methods of activation may be used in the practice of the invention and include for example, preformed symmetrical anhydrides (PSA),
5 preformed mixed anhydride (PMA), acid chlorides, active esters, and in situ activation of the carboxylic acid, as set forth in Fields and Noble, 1990, Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids, Int. J. Pept. Protein Res. 35:161-214.

The use of Fmoc amino acids is but one strategy of peptide synthesis. A Boc strategy (t-butyloxycarbonyl-protected α -amino group) may also be used to prepare a library
10 of peptides bound to the solid phase support (e.g., Geysen et al., 1987, J. Immunol. Methods 102:259274.)

The completeness of coupling should be assessed. Those skilled in the art would be familiar with the well known quantitative monitoring tests such as ninhydrin (the Kaiser test), picric acid, 2,4,6-trinitrobenzenesulfonic (TNBS), fluorescamine, and chloranil, which
15 are based on reagent reaction with free amino groups to produce a chromophoric compound. If amino acids (e.g., Pro and Hyp) are used, isatin monitoring is a preferred method. Fields and Noble, supra. Quantification of reaction completeness may be monitored during the course of the reaction, e.g., as described by Salisbury et al. (International Patent Publication No. WO91/03485).

20 With Fmoc synthesis, the Kaiser test is preferred. In the Kaiser test, a sample from each tube can be tested with ninhydrin reagent obtained from Pierce Chemical in the method set forth by Sarin et al. (1981, Anal. Biochem. 117:147-157).

If the coupling reaction is incomplete as determined by this test, the reaction can be forced to completion by several methods familiar to those in the art, including (a) a second
25 coupling using a one to five fold excess of protected amino acid, (b) an additional coupling using different or additional solvents (e.g., trifluoroethane), or (c) the addition of chaotropic salts, e. g., NaClO_4 or LiBr (Klis and Stewart, 1990, Peptides: Chemistry, Structure and Biology, Rivier and Marshall, eds., ESCOM Publ., p. 904-906).

After the coupling reaction is complete the aliquots of the solid phase support/first
30 amino acid combinations are thoroughly mixed. Thorough mixing is obtained when a uniform mixture of the aliquots results, preferably by mixing the aliquots in a single reaction

vessel. Although any means of thorough mixing is within the scope of this invention and a variety of means are familiar to those of ordinary skill in the art, preferable means may include, for example, vortexing or shaking in any commercially available motorized shaker apparatus or by bubbling with inert gas, e.g., nitrogen or argon.

5 The resulting mixture is divided into at least two aliquot parts. These aliquot parts are equal in volume and, if the mixing was sufficiently thorough, should contain substantially equal amounts of the solid phase support/first amino acid combinations. Using the dipeptide example, each aliquot will contain essentially equal amounts of the bead-glycine combination and the bead-proline combination.

10 To each aliquot is separately introduced a second set of amino acids. This second set may consist of (a) the same amino acids added in the first set, i.e., glycine or proline; (b) a different set of amino acids, e.g., tryptophan or leucine; (c) only one type of amino acid, e.g., isoleucine.

15 As with the first set of amino acids, the second set of amino acids is completely coupled individually to the solid phase support/first amino acid combination of each aliquot to form peptides comprising a first amino acid and a second amino acid. As with the prior coupling, the coupling may be accomplished by any technique used in the art for such reactions. Using the dipeptide example discussed above: (a) with the addition of the same set of amino acids, the resulting peptides are either glycine-glycine, glycine-proline, 20 proline-glycine, or proline-proline; (b) with a different set of amino acids, the resulting peptides are either Gly-Trp, Gly-Leu, Pro-Trp or Pro-Leu; (c) with one type of amino acid, the resulting peptides are Gly-Ile or Pro-Ile.

25 This method can be repeated as many times as there are amino acids to add. If the peptide of interest is a tetrapeptide X-X-X-Trp, where X is either valine, serine or alanine, for example, the method can be repeated three times to get the X-X-X-Trp tetrapeptide. If a hexapeptide is desired, the process is repeated six times. If the hexapeptide is to be comprised of five different amino acids, the method could be employed using five aliquots, each containing a different amino acid, at each coupling step. If, however, the hexapeptide is to be comprised of any of the basic set of twenty amino acids, the method could be 30 employed using twenty aliquots at each coupling step.

The method of the peptide synthesis of the invention can be used with solid phase

supports to which an amino acid either is or is not already attached. In addition, one may use a linker that has already been attached to the solid phase support. One common support to which an amino acid is already bound is the β -alanine-PAM-resin (obtained from Bachem Biochemical). These resins are available from numerous commercial sources or made in the
5 laboratory by one knowledgeable in the art of peptide synthesis.

If a solid phase support/amino acid combination or solid phase/support linker is used as the initial reagent, it is divided into at least two aliquots, each of which receives an amino acid from a first set of amino acids. As described above, the first set of amino acids is completely coupled to substantially all binding sites on the solid phase support/amino acid
10 combination or solid phase support/linker and the aliquots containing these newly added amino acids are thoroughly mixed. As described above, the mixture is divided into at least two aliquots, each aliquot receives an amino acid from a second set of amino acids, and the coupling reaction is repeated to form a growing peptide. As described above, the process can be repeated as many times as is desired to produce the peptides of interest.

15 This method may be used for the synthesis of random peptides as well as for the synthesis of a peptide library that comprises pre-determined sequences. The synthesis of predetermined sequences involves the use of specific N^α -Boc-, N^α -Fmoc- or other appropriately protected amino acids during specific coupling steps. For example, one may select amino acids at specific coupling steps such that the resulting peptides will have a
20 probability or preference for a particular secondary structure, e.g., β -sheet, α -helix, β -turn, etc. For example, α -helix would be preferred if Glu, Ala, Leu, His, Trp are used as preferred amino acids; on the other hand β -sheets would be preferred if Val, Ile, Tyr and Met are used. Alternatively, if Gly, Asn, Ser, Pro, Asp are used, a β -turn structure would be preferred. Other examples could be considered such as acidic amino acids near the
25 N-terminal, and basic amino acids near the C-terminal, to stabilize an α -helix. D-amino acids can stabilize certain turns, and numerous other structural motifs can be incorporated. It may even be possible to prepare cyclic peptide libraries with disulfide, lactam, lactone or other ring closing moieties.

It is to be emphasized that the method of the instant invention allows the synthesis of
30 peptides such that each solid phase support, such as a resin bead, will contain only one species of peptide. The method assures that each individual resin bead is in contact with

only one Fmoc amino acid during each coupling cycle and that the coupling is driven to completion. The one bead-one peptide synthesis allows increased sensitivity and efficiency of isolating the peptide that is specific for the entity to which it binds.

The use of N^α-Fmoc-Ser(Ac₃-α-D-GalpNAc-OPfp) and

- 5 N^α-Fmoc-Thr(Ac₃-α-D-GalpNAc)-OPfp and their application in multiple-column solid-phase synthesis of O-glycopeptides is well known in the art. (Peters et al. (1992) 1:1163-1171). The protecting group pattern of these building blocks is suitable for solid-phase glycopeptide synthesis. The use of Fmoc allows deprotection of the α-amino group under mild conditions with morpholine to occur without β-elimination of the carbohydrate.

- 10 In one aspect of the invention, the library of peptides comprises at least 3 amino acids. In another embodiment, the amino terminal amino acid is a serine to which a carbohydrate is o-glucosidically linked. In yet another embodiment, the amino terminal peptide is N-acetylated. In a further embodiment, the penultimate amino acid is a serine to which a carbohydrate is o-glucosidically linked. In yet a further embodiment, the
15 carbohydrate is a fucose moiety.

Solid Phase Supports and Linkers for Use in a Glyco-Peptide Library

- A solid phase support for use in the present invention will be inert to the reaction conditions for bio-oligomer synthesis, e.g., peptide synthesis or oligonucleotide synthesis, or
20 both. A solid phase support for use in the present invention must have reactive groups in order to attach a monomer subunit, or for attaching a linker or handle which can serve as the initial binding point for a monomer subunit. In one embodiment, the solid phase support may be suitable for use, i.e., it may serve as a carrier for or support for direct applications of the bio-oligomer library (e.g., TentaGel, Rapp Polymere, Tübingen, Germany; see Section
25 5.8., infra). In a particular embodiment, the solid phase support may be palatable and orally consumable. In another embodiment, the solid phase support may be a useful chromatographic support.

- As used herein, solid phase support is not limited to a specific type of support. Rather a large number of supports are available and are known to one of ordinary skill in
30 the art. Solid phase supports include silica gels, resins, derivatized plastic films, glass beads, cotton, plastic beads, alumina gels. A suitable solid phase support may be selected

on the basis of desired end use and suitability for various synthetic protocols. For example, for peptide synthesis, solid phase support may refer to resins such as polystyrene (e.g., PAM-resin obtained from Bachem Inc., Peninsula Laboratories, etc.), POLYHIPE® resin (obtained from Aminotech, Canada), polyamide resin (obtained from Peninsula Laboratories), polystyrene resin grafted with polyethylene glycol (TentaGel®, Rapp Polymere, Tübingen, Germany) or polydimethylacrylamide resin (obtained from Milligen/Bioscience, California). In a preferred embodiment for peptide synthesis, solid phase support refers to PEGA resin (BACHEM) as described in Meldal, et al., Tetrahedron Lett. 33:3077-3080 (1992).

10 The solid phase supports of the invention may also comprise a linker. As used herein, a linker refers to any molecule that provides spatial distance between the support and the peptide to be synthesized. Linkers can be covalently attached on the solid phase support prior to coupling with a N^α-Boc or N^α-Fmoc or otherwise appropriately protected amino acids. Various linkers can be used to attach the oligomer to solid phase support. Examples
15 of linkers include aminobutyric acid, aminocaproic acid, 7-aminoheptanoic acid, and 8-aminocaprylic acid. Fmoc-aminocaproic acid is commercially available from Bachem Biochem, and is the preferred embodiment. In a further embodiment, linkers can additionally comprise one or more β-alanines as spacers. In addition, the solid-support could be modified to meet specific requirements for the particular purpose of bioassay or
20 detection. Modification of solid phase support may be made by incorporation of a specific linker. For example, modified solid phase support could be made acid-sensitive, base-sensitive, nucleophilic electrophilic sensitive, photosensitive oxidation sensitive or reduction sensitive.

In addition to the linkers described above, selectively cleavable linkers may be
25 employed. Use of an ultraviolet light sensitive linker, ONb, is shown in Section 12, *infra* (see Sarany and Albenicia, 1985, J. Am. Chem. Soc., 107:4936-4942). Other cleavable linkers require hydrogenolysis or photolysis. Examples of photosensitive (photocleavable) linkers are found in Wang (1976, J. Org. Chem. Soc. 41:32-58), Hammer et al. (1990, Int. J. Pept. Protein Research 36:31-45), and Ereib-Cordonier et al. (1990, in Peptides-Chemistry and Biology Rivier and Marshall, eds., pp. 895-897). Landen (1977, Methods Enzymology,
30 47:145-149) used aqueous formic acid to cleave Asp-Pro bonds; this approach has been used

to characterize T-cell determinants in conjunction with the Geysen pin synthesis method (Van der Zee et al., 1989, Eur. J. Immunol. 191:43-47). Other potential linker groups cleavable under basic conditions include those based on p-(hydroxymethyl) benzoic acid (Atherton et al., 1981, J. Chem. Soc. 1:538-546) and hydroxyacetic acid (Baleaux et al., 1986, Int. Pept. Protein Res. 28:22-28). Geysen et al. (1990, J. Immunol. Methods 134:23-33) reported peptide cleavage by a diketopiperazine mechanism. An enzyme may specifically cleave a linker that comprises a sequence that is sensitive or a substrate for enzyme cleavage, e.g., protease cleavage of a peptide; endonuclease cleavage of an oligonucleotide. In certain instances, one may derivatize 10-50% of the resin by substitution with the cleavable linker, and the remaining 50-90% substituted with a noncleavable linker to ensure that enough peptide will remain after cleavage of linker be left behind for sequencing.

A solid phase support for use in the present invention may further comprise a bio-oligomer of interest, to which a random subunit sequence may be added. The pre-attached bio-oligomer may be selected according to the methods described herein, or may comprise a sequence known to embody desired properties.

Methods of Detection and Identification of Bio-Oligomer Glyco-Peptides of Interest

In addition to providing a collection of bio-oligomer glyco-peptides or a library and methods of synthesis thereof, the present invention further comprises methods of screening a collection or library of bio-oligomer glyco-peptides to identify bio-oligomers within the collection or library that demonstrate a biological activity of interest.

The present invention allows identification of bio-oligomer ligands that bind acceptor molecules. As used-herein, the term "acceptor molecule" refers to any substance which binds to a bio-oligomer ligand. Acceptor molecules may be a biologic macromolecule such as, but not limited to, lectins, antibodies, receptors, viruses or selectins. In addition, acceptor molecules may be a chemical compound such as, but not limited to, proteins, carbohydrates, nucleic acids, lipids, drugs, metals or small molecules.

The collection of or library of bio-oligomer glyco-peptides of the invention can potentially interact with many different acceptor molecules. By identifying the particular

bio-oligomer species to which a specific acceptor molecule binds, it is possible to physically isolate the bio-oligomer species of interest.

Because only a small number of bio-oligomers will be removed during each screening/detection/isolation step, the majority of the beads will remain in the pool.

5 Therefore, the bio-oligomer glyco-peptide library can be reused multiple times. If different color or identification schemes are used for different acceptor molecules (e g., with fluorescent reporting groups such as fluorescein (green), Texas Red (Red) and DAPI (blue) tagged on the acceptors), and with suitable excitation filters in the fluorescence microscope or the fluorescence detector, different acceptors (receptors) can be added to a peptide library
10 and evaluated simultaneously to facilitate rapid screening for specific ligands. These strategies not only reduce cost, but also increase the number of acceptor molecules that can be screened.

In the method of the invention, an acceptor molecule of interest is introduced to the collection of or library of bio-oligomers where it will recognize and bind to one or more
15 bio-oligomer species within the library. Each bio-oligomer species to which the acceptor molecule binds will be found on a single solid phase support so that the support, and thus the bio-oligomer, can be readily identified and isolated.

The bio-oligomer can be isolated by any conventional means known to those of ordinary skill in the art and the invention is not limited by the method of isolation. For
20 example and not by way of limitation, it is possible to physically isolate a solid phase support/bio-oligomer combination that exhibits the strongest physio-chemical interaction with the specific acceptor molecule. In one embodiment based on physio-chemical interaction, a solution of a specific acceptor molecule added to a random peptide library which is equivalent to approximately 10^5 to 10^7 solid phase supports. The acceptor
25 molecule is incubated with the resin for a time sufficient to allow coupling between the peptide and antibody, for example, one hour at 22°C. Thereafter, the acceptor molecule coated bio-oligomer/solid phase support is isolated. More specific embodiments are set forth in the following methods.

The invention having been described, the following examples are offered to illustrate the
30 subject invention by way of illustration, not by way of limitation.

Examples

I. Synthesis and characterization of Fmoc-Ser(β -Fuc(Ac₃)). (Figures 1A-1E)

N-Carboxybenzoyloxy-3-O-(2,3,4-tri-O-acetyl- β -L-fucopyranosyl)-L-serine Benzyl Ester (Figure 1C).

- 5 To a solution of commercial N-(carboxybenzoyloxy)-3-O-(2,3,4-tri-O-benzyl- α -L-fucopyranosyl)-L-serine benzyl ester (Bachem, 2.17 gm, 6.61 mmol) in dry acetonitrile (17 ml) containing powdered drierite (1.6 gm) were added, sequentially under nitrogen atmosphere, mercuric bromide (2.86 gm, 7.93 mmol), mercuric cyanide (2.00 gm, 7.93 mmol) and a solution of acetobromofucose (2.33 gm, 6.61 mmol) in dry acetonitrile
- 10 (10 ml). The reaction mixture was stirred for 15 h at room temperature and then filtered through celite. Evaporation of the solvent gave a residue, which was extracted with dichloromethane and washed successively with saturated aqueous potassium chloride, saturated aqueous sodium bicarbonate and water. The organic layer was dried, filtered, and evaporated to dryness. The white solid was purified by chromatography on silica gel using
- 15 hexane-ethyl acetate 2:1 as eluent. Pure N-Carboxybenzoyloxy-3-O-(2,3,4-tri-O-acetyl- β -L-fucopyranosyl)-L-serine Benzyl Ester (2.1 gm, 52.9%) was obtained as a white solid. $R_f=0.38$ (hexane:ethyl acetate 2:1, developed 3 times). $^1\text{H-NMR}$ (CDCl_3): δ 7.45-7.30 (10 H, aromatic), 5.75 (d, 1 H, $J_{\text{NH},2}=9.0$ Hz, NH), 5.26 (d, 1 H, $J_{\text{gem}}=12$ Hz, PhCH), 5.18 (dd, 1 H, $J_{3,4}=3.0$, $J_{4,5}=1.0$ Hz, H-4), 5.13-5.07 (m, 4
- 20 H, 3 x PhCH and H-2), 4.91 (dd, 1 H, $J_{2,3}=10.5$ Hz, H-3), 4.54 (ddd, $J=3.0$, 3.0, 9.0 Hz, serine CHN), 4.21 (d, 1 H, $J=8.0$ Hz, H-1), 4.06 (m, 2 H, serine CH_2), 3.64 (dq, $J_{5,6}=6.5$ Hz, H-5), 2.16, 2.00 and 1.97 (each s, 3 H, Ac), 1.17 (d, 3 H, H-6). 3-O-(2,3,4-tri-O-acetyl- β -L-fucopyranosyl)-L-serine (Figure 1D).

- A solution of N-Carboxybenzoyloxy-3-O-(2,3,4-tri-O-acetyl-
- 25 β -L-fucopyranosyl)-L-serine Benzyl Ester (600 mg, 1.0 mmol) in 98% ethanol (15 ml) containing 5% Pd/C (300 mg) was hydrogenated for 16 h at room temperature and at 1 atmospheric pressure. The catalyst was collected on celite and washed with several portions of 98% ethanol. The filtrate and washings were combined and concentrated to dryness to give 3-O-(2,3,4-tri-O-acetyl- β -L-fucopyranosyl)-L-serine (306.6 mg, 81.6%) as a white
- 30 powder $R_f=0.34$ (dichloromethane:methanol:water, 60:35:3). $^1\text{H-NMR}$ (CD_3OD): δ 5.23 (dd, 1H, $J_{3,4}=3.0$, $J_{4,5}=1.0$ Hz, H-4), 5.14-5.02 (m, 2 H, H-2 and 3), 4.68 (d, 1 H, $J_{1,2}=7.5$ Hz,

H-1). 4.24 (dd, 1 H, $J_{gem}=7.5$ Hz, H-1), 4.24 (dd, 1 H, $J_{gem}=10.5$, $J_{CH,CHN}=2.0$ Hz, serine \underline{CH}), 4.13-4.04 (m, 2 H, serine \underline{CHH} and \underline{CHN}), 4.01 (dq, $J_{5,6}=6.5$ Hz, H-5), 2.13, 2.05 and 1.93 (each s, 3 H, Ac), 1.19 (d, 3 H, H-6).

N-(9-Fluorenylmethyloxycarbonyl)-3-O-(2,3,4-tri-O-acetyl- β -L-fucopyranosyl)-L-serine

5 (Figure 1E).

A solution of 3-O-(2,3,4-tri-O-acetyl- β -L-fucopyranosyl)-L-serine (Figure 1D) (209.6 mg, 0.82 mmol) and Fmoc N-hydroxysuccinimide ester (9-fluorenylmethyl-N-succinimidyl carbonate) (375.7 mg, 1.63 mmol) in dry pyridine (25 ml) was stirred for 15 h at room temperature. Evaporation and co-evaporation of the reaction mixture with toluene left a
10 syrup which was purified by chromatography on silica gel using dichloromethane-methanol 95:5 as eluent. Pure

N-(9-Fluorenylmethyloxycarbonyl)-3-O-(2,3,4-tri-O-acetyl- β -L-fucopyranosyl)-L-serine (294 mg, 88%) was obtained as a white powder, $R_f=0.40$ (9:1, dichloromethane: methanol).

1H -NMR (CD_3OD): δ 7.82-7.25 (m, 8 H, aromatic), 5.18 (m, 1 H, sec. order, H-4),

15 5.08-4.98 (m, 2 H, sec. order, H-2, 3), 4.50 (d, 1 H, $J_{1,2}=7.5$ Hz, H-1), 4.44-3.95 (complex, 6 H, Fmoc-H and serine H's), 3.83 (q, $J_{5,6}=6.25$ Hz, H-6), 2.11, 1.99 and 1.92 (each s, 3 H, Ac), 1.10 (d, 3 H, H-6). ^{13}C : δ 102.6 (C-1), 72.5, 71.8 and 70.3 (C-2, 3 and 4), 71.5 and 67.9 (F_{MOC} and serine $\underline{CH_2}$), 56.5 (serine \underline{CHN}), 20.8, 20.5 and 20.4 ($COCH_3$), 16.3 (C-6).

20 II. Synthesis and characterization of Fmoc-Ser (α -Fuc(Ac₃)) (Figures 2A-2F)

N-(carboxybenzoyloxy)-3-O-(2,3,4-tri-O-benzyl- α -L-fucopyranosyl)-L-serine benzyl ester. (Figure 2-A). N-carboxybenzoyloxy-L-serine benzyl ester (dried under vacuum overnight with phosphorus pentoxide, 5.04 g, 15.3 mmol) and tetraethylammonium bromide (3.47 g, 16.83 mmol) were dissolved in dichloromethane (30 mL) and dimethylformamide (2 mL)
25 containing crushed 4A molecular sieves (15 g). The solution was stirred under argon for thirty minutes. To this slurry was added freshly prepared 2,3,4-tri-O-benzyl-fucopyranosyl bromide (U. Spohr and R.U. Lemieux, Carbohydr. Res., 174 (1988) 211). (38.3 mmol) in dichloromethane (20 mL) and the reaction allowed to stir for 15 hours under argon. Methanol (10 mL) was added and stirring continued for thirty minutes after which the
30 reaction was filtered, diluted with dichloromethane, and washed with water and brine. After drying and solvent removal, the residue was chromatographed (3:1 hexane:ethyl acetate) to

give N-(carboxybenzoyloxy)-3-O-(2,3,4-tri-O-benzyl- α -L-fucopyranosyl)-L-serine benzyl ester (9.49 g, 85%) as an oil which solidified upon standing, $[\alpha]_D -57.7$ ($c=0.91$, chloroform), $R_f=0.30$ (3:1 hexane:ethyl acetate). $^1\text{H-NMR}$ (CDCl_3): δ 7.10-7.15 (m, 25H, Ph), 6.09 (d, 1H, $J_{\text{NH,CH}}=9.5$ Hz, NH), 5.23 (d, 1H, $J_{\text{gem}}=11.5$ Hz, PhCH_2), 5.13 (s, 2H, PhCH_2), 5.05, 4.92, 4.76, 4.77 (d, 1H, $J_{\text{gem}}=11.5$ Hz, PhCH_2), 4.52-4.69 (m, 5H, 3 PhCH_2 , serine CHNH , H-1), 4.16 (dd, 1H, $J_{\text{gem}}=10$ Hz, $J_{\text{vic}}=2.5$ Hz, serine CH_2), 3.94 (dd, 1H, $J_{1,2}=4$ Hz, $J_{2,3}=10$ Hz, H-2), 3.60 (dd, 1H, $J_{2,3}=10$ Hz, $J_{3,4}=2.5$ Hz, H-3), 3.48 (d, 1H, $J_{\text{gem}}=10$ Hz, $J_{\text{vic}}=3.5$ Hz, serine CH_2), 3.29-3.40 (m, 2H, H-4, H-5), 0.91 (d, 3H, $J_{5,6}=6.5$ Hz). $^{13}\text{C-NMR}$: δ 170.10 (C=O ester), 156.30 (C=O, carbamate), 138.88, 138.53, 136.35, 135.51 (Ph quat.), 128.62, 128.57, 128.50, 128.38, 128.19, 128.14, 127.83, 127.64, 127.54 (Ph methine) 98.87 (C-1), 78.87 (C-4), 77.36 (C-3), 76.50 (C-2), 74.74, 73.31, 73.23 (PhCH_2), 69.03 (serine CH_2), 67.15, 67.07 (PhCH_2), 66.68 (C-5), 54.51 (serine CHNH), 16.48 (C-6).

Anal. Calc. for $\text{C}_{44}\text{H}_{47}\text{NO}_9$ (733.86): C, 72.01; H, 6.46; N, 1.91. Found: C, 72.34; H, 6.45; N, 1.93.

- 3-O-(α -L-fucopyranosyl)-L-serine. (Figure 2B). The protected glycoamino acid A (6.5 g, 8.86 mmol) was dissolved in ethanol (75 mL) and water (20 mL). 2N HCl (4.5 mL) and 10% palladium on carbon (2.5 g) were added and the solution stirred under a flow of hydrogen for 24 hours. After completion of the reaction, the catalyst was filtered away and the solvent evaporated to give 3-O-(α -L-fucopyranosyl)-L-serine in quantitative yield (2.22 g) as a white solid. $^1\text{H-NMR}$ (D_2O): 4.90 (d, 1H, $J_{1,2} = 3.5$ Hz, H-1), 4.20-4.29 (m, 2H, serine CH_2 , serine CHNH), 3.93 (q, 1H, $J_{5,6} = 6.5$ Hz, H-5), 3.75-3.85 (m, 4H, serine CH_2 , H-2, H-3, H-4), 1.19 (d, 3H, $J_{5,6} = 6.5$ Hz, H-6). $^{13}\text{C-NMR}$: δ 171.39 (C=O), 98.83 (C-1), 72.48 (C-4), 70.28 (C-3), 68.77 (C-2), 68.01 (C-5), 65.71 (serine CH_2), 54.37 (serine CHNH_2), 16.01 (C-6). N-(9-Fluorenylmethyloxycarbonyl)-3-O-(α -L-fucopyranosyl)-L-serine. (Figure 2C). 3-O-(α -L-fucopyranosyl)-L-serine (2.22 g, 8.86 mmol) was dissolved in acetone (100 mL) and water (50 mL). Sodium bicarbonate (745 mg, 8.86 mmol) and 9-fluorenylmethyl-N-succinimidyl carbonate (6.0 g, 17.8 mmol) was added and the solution stirred overnight. The reaction was extracted with ethyl acetate, the pH of the aqueous layer brought to 9 by the addition of sodium hydroxide and the aqueous layer lyophilized to give N-(9-Fluorenylmethyloxycarbonyl)-3-O-(α -L-fucopyranosyl)-L-serine, $R_f = 0.21$ (2:1 dichloromethane:methanol) which was not further purified. $^1\text{H-NMR}$ (CD_3OD): 7.15-7.70

(m, 8H, Fmoc aromatic), 4.64 (d, 1H, $J_{1,2} = 3.5$ Hz, H-1), 4.21-4.33 (m, 3H, 2 Fmoc CH_2 , serine CHNH), 4.06-4.15 (m, 2H, serine CH_2 , Fmoc CH), 3.80 (q, 1H, $J_{5,6} = 6.5$ Hz, H-5), 3.65 (dd, 1H, $J_{1,2} = 3.5$ Hz, $J_{2,3} = 9.5$ Hz, H-2), 3.56 (dd, 1H, $J_{2,3} = 9.5$ Hz, $J_{3,4} = 2.5$ Hz, H-3), 3.50 (d, $J_{3,4} = 2.5$ Hz, H-4), 3.46 (dd, 1H, $J_{\text{gem}} = 9.5$ Hz, $J_{\text{vic}} = 1$ Hz, serine CH_2), 1.08
 5 (d, 3H, $J_{5,6} = 6.5$ Hz, H-6).

N-(9-Fluorenylmethyloxycarbonyl)-3-O-(α -L-fucopyranosyl)-L-serine allyl ester. (Figure 2D). N-(9-Fluorenylmethyloxycarbonyl)-3-O-(α -L-fucopyranosyl)-L-serine was dissolved in dimethylsulfoxide (100 mL) and allyl bromide (25 mL) added. After stirring for 4 hours, the reaction was diluted with ethyl acetate and washed with water and brine. The organic
 10 layer was evaporated to dryness and the residue chromatographed (9:1 dichloromethane:methanol) to give N-(9-Fluorenylmethoxy-carbonyl)-3-O-(α -L-fucopyranosyl)-L-serine allyl ester (2.32 g, 51% from 3-O-(α -L-fucopyranosyl)-L-serine) as a yellow foam, $R_f = 0.51$ (9:1 dichloromethane:methanol). $^1\text{H-NMR}$ (CD_3OD): 7.28-7.81 (m, 8H, Fmoc aromatic), 5.93
 15 (1H, H_c allyl), 5.37 (1H, H_a allyl), 5.27 (1H, H_b allyl), 4.80 (d, $J_{1,2} = 3.5$ Hz, H-1), 4.62-4.71 (m, 2H, H_d and H_e allyl), 4.59 (t, $J_{\text{vic}} = 2.5$ Hz, CHNH), 4.47, 4.38 (dd, 1H, $J_{\text{gem}} = 10$ Hz, $J_{\text{vic}} = 7$ Hz, Fmoc CH_2), 4.22-4.32 (m, 2H, H-2, H-3), 3.72-3.82 (m, 2H, Fmoc CH , H-5), 3.61-3.68 (m, 2H, H-4, serine CH_2), 3.58 (dd, 1H, $J_{\text{gem}} = 9$ Hz, $J_{\text{vic}} = 2.5$ Hz, serine CH_2), 1.23 (d, 3H, $J_{5,6} = 6.5$ Hz, H-6).

20 N-(9-Fluorenylmethyloxycarbonyl)-3-O-(2,3,4-tri-O-acetyl- α -L-fucopyranosyl)-L-serine allyl ester. (Figure 2E). To a solution of N-(9-Fluorenylmethyloxycarbonyl)-3-O-(α -L-fucopyranosyl)-L-serine allyl ester (3.68 g, 7.18 mmol) in dichloromethane (75 mL) was added pyridine (7 mL, 86.15 mmol) and acetic anhydride (8.15 mL, 86.15 mmol). After stirring overnight, the reaction was diluted with dichloromethane then washed with water,

25 bicarbonate and brine. The organic layer was evaporated to dryness and the residue chromatographed (2:1 ethyl acetate:hexane) to give

N-(9-Fluorenylmethyloxycarbonyl)-3-O-(2,3,4-tri-O-acetyl- α -L-fucopyranosyl)-L-serine allyl ester (3.97 g, 87%) as a white foam, $[\alpha]_D - 77.0$ ($c = 1.65$, chloroform), $R_f = 0.60$ (1:1 hexane:ethyl acetate). $^1\text{H-NMR}$ (CDCl_3): 7.28-7.80 (m, 8H, Fmoc aromatic), 5.96 (1H, H_c allyl), 5.59 (d, 1H, $J_{\text{NH,CH}} = 8.5$ Hz, NH), 5.38 (1H, H_a allyl), 5.28 (1H, H_b allyl),
 30 5.18-5.28 (m, 2H, H-3, H-4), 5.13 (d, 1H, $J_{1,2} = 3.5$ Hz, H-1), 5.03-5.11 (m, 1H, H-2),

4.63-4.79 (m, 2H, H_d and H_e allyl), 4.60 (ddd, J_{CH,NH} = 8.5 Hz, J_{vic} = 2.5 Hz, J_{vic} = 3.0 Hz, CHNH), 4.49, 4.39 (dd, 1H, J_{vic} = 7 Hz, J_{gem} = 10.5 Hz, Fmoc CH₂), 4.23 (t, 1H, J_{vic} = 7 Hz, Fmoc CH) 4.20 (dd, 1H, J_{vic} = 2.5 Hz, J_{gem} = 10.5 Hz, serine CH₂), 4.03 (q, 1H, J_{5,6} = 6.5 Hz, H-5), 3.68 (dd, 1H, J_{vic} = 3.0 Hz, J_{gem} = 10.5 Hz, serine CH₂), 2.17, 2.02, 1.98 (s, 3H, acetate CH₃), 1.10 (d, 3H, J_{5,6} = 6.5 Hz, H-6). ¹³C-NMR: δ 170.54, 170.38, 169.96, 169.41 (C=O ester), 155.87 (C=O carbamate), 143.83, 143.66, 141.33 (Ph quaternary), 131.37 (CH₂ = CHCH₂O), 127.77, 127.11, 125.03, 120.03 (Ph methine), 119.47 (CH₂=CHCH₂O), 96.84 (C-1), 70.89 (C-4), 68.51 (CH₂=CHCH₂O), 68.02 (C-3), 67.95 (C-2), 67.19 (Fmoc CH₂), 66.52 (serine CH₂), 64.83 (C-5), 54.31 (serine CHNH), 47.16 (Fmoc CH), 20.69, 20.62 (acetate CH₃), 15.83 (C-6).

Anal. Calc. for C₃₃H₃₇NO₁₂ (639.66): C, 61.97; H, 5.83; N, 2.19. Found: C, 62.02; H, 5.75; N, 2.21. N-(9-Fluorenylmethyloxycarbonyl)-3-O-(2,3,4,-tri-O-acetyl-α-L-fucopyranosyl)-L-serine. (Figure 2F). N-(9-Fluorenylmethyloxy-carbonyl)-3-O-(2,3,4-tri-O-acetyl-α-L-fucopyranosyl)-L-serine allyl ester (3.70 g, 5.79 mmol) was dissolved in tetrahydrofuran (75 mL) and then morpholine (1 mL, 11.58 mmol) and tetrakis triphenylphosphine palladium (670 mg, 0.579 mmol) were added. After stirring for five minutes, the reaction was diluted with dichloromethane then washed with 0.5 N hydrochloric acid, water and brine. The organic layer was evaporated to dryness and the residue chromatographed (9:1 dichloromethane:methanol) to give N-(9-Fluorenylmethyloxycarbonyl)-3-O-(2,3,4,-tri-O-acetyl-α-L-fucopyranosyl)-L-serine (3.11 g, 90%) as a white foam, F_r = 0.43 (9:1 dichloromethane:methanol). ¹H-NMR (CD₃OD): 7.16-7.73 (m, 8H Fmoc aromatic) 5.06-5.23 (m, 2H, H-3, H-4), 4.88-4.98 (m, 2H, H-1, H-2), 4.35, 4.28 (dd, 1H, J_{gem} = 10 Hz, J_{vic} = 6.5 Hz, Fmoc CH₂), 4.02-4.18 (m, 3H, H-5, Fmoc CH, serine CHNH), 3.91 (dd, 1H, J_{gem} = 9.5 Hz, J_{vic} = 9.5 Hz, J_{vic} = 5.5 Hz, serine CH₂), 3.68 (dd, 1H, J_{gem} = 9.5 Hz, J_{vic} = 3.0 Hz, serine CH₂), 2.04 (s, 3H acetate CH₃), 1.86 (s, 6H, 2 acetate CH₃), 0.95 (d, 3H, J_{5,6} = 6.5 Hz, H-6). ¹³C-NMR: δ 172.29, 171.98, 171.64 (C=O, ester), 158.34 (C=O, carbamate), 145.33, 145.23, 142.57 (Ph quaternary), 128.76, 128.22, 126.11, 120.93 (Ph methine), 97.33 (C-1), 72.51 (C-4), 69.55 (C-3), 69.38 (C-2), 67.89 (Fmoc CH₂, serine CH₂), 65.81 (C-5), 56.85 (serine CHNH), 48.35 (Fmoc CH), 20.71, 20.63, 20.45 (acetate CH₃), 16.14 (C-6), FAB-MS m/z 622.16 (M+Na)⁺, 3.47%; 638.17 (M+K)⁺, 100%; (C₃₀H₃₃NO₁₂ requires M, 599.20).

III. TLC was performed on Merck Silica Gel 60 F₂₅₄ with detection by charring with sulfuric acid. N,N-Dimethylformamide (DMF) was freshly distilled by fractional distillation at reduced pressure and kept over 3 molecular sieves. Light petroleum was the 60-80 °C fraction. All organic solvents were of p.a. quality from Labscan (Ireland). Concentrations were performed under reduced pressure at temperatures < 30 °C (bath).
p-((α -Fluoren-9-ylmethoxycarbonyl amino)-2,4-dimethoxybenzyl) phenoxyacetic acid (Rink-linker) and suitably protected N^o-Fmoc amino acids were purchased from NovaBiochem (Switzerland), O-(1H-benzotriazol-1-yl)-N,N,N',N'- tetramethyluronium tetrafluoroborate (TBTU) and 3,4-dihydro-3-hydroxy-4-oxo-1,2,3- benzotriazine (Dhbt-OH) from FLUKA (Switzerland), N-ethyl-morpholine from MERCK (Germany). The peptides and the glycopeptides were hydrolysed with 6 mol dm⁻³ HCl at 110 °C for 24 h and the amino acid composition was determined on a Pharmacia LKB Alpha Plus amino acid analyzer, Asn was determined as Asp. NMR spectra were recorded on a Bruker AM-500 or a Bruker AMX-600 MHz spectrometer. The ¹H and ¹³C resonances were assigned by ¹H, ¹³C, ¹H-¹H COSY, ¹H-1H Double Quantum Filtered Phase Sensitive COSY, ¹³C-¹H correlation. NMR spectra were recorded in H₂O/CD₃COOD-mixtures at pH (pD) = 2.8 measured at room temperature using a PHM63 Digital pH Meter (Radiometer) equipped with an INGOLD electrode with no correction for isotope effects. HPLC was performed on a Waters system with a 600 controller, a 410 differential refractometer or a 991 photodiode array detector, both equipped with preparative flow cells, and a model 600 pump with modified 80 cm³/min pump heads. The system was fitted with switchable analytical RCM (8 x 10) and Deltapak (19 x 300) columns and a preparative radial pack module for columns (50x300 mm) packed with reversed phase C₁₈. Solvent system A: 0.1% trifluoroacetic acid (TFA) and B: 0.1% TFA in 90% acetonitrile-10% water, was employed for both analytical (1 cm³/min) and preparative (10 or 20 cm³/min) separations and detection was at 215 nm.

IV. Solid-phase synthesis of Ac-Ser(α -L-Fuc)-Ala-Asp-NH₂, and Ac-Ser(β -L-Fuc)-Ala-Asp-NH₂.

The plastic syringe technique, which is a simple and cheap alternative to automatic peptide synthesizers. A 10 cm³ disposable plastic syringe A (without piston) was fitted with a sintered teflon filter (pore size 70 μ m) and the outlet connected to the outlet of a 50 cm³

plastic syringe **B** via a teflon tube with luer adapters. Syringe **B** was used as a waste syringe to remove solvents and unused reagents. PEGA-resin (0.386 g, 0.14 mmol/g) was placed in syringe **A** and allowed to swell in DMF (10 cm³) which was carefully added from the top and removed from the bottom by suction with syringe **B**. After thorough rinse with

5 DMF (3 x 5 cm³) Rink-linker (114 mg, 0.21 mmol), TBTU (62 mg, 0.199 mmol) and N-ethyl-morpholine (48 mm³, 0.386 mmol) was dissolved in DMF (2.5 cm³) and after 15 min added to the resin. After 2 h the resin was rinsed with DMF (10x4 cm³), deprotected with 50% morpholine/DMF (3 cm³, 3 min, removed, 3 cm³ 25 min) and washed again (10x3 cm³). N^αFmoc-L-Asp(Bu^t)-OPfp (173 mg, 0.3 mmol) and Dhbt-OH (8.8 mg, 0.054 mmol)

10 were dissolved in DMF (4 cm³) and the mixture added to the resin. The acylation time was determined by observation of the yellow color formed between Dhbt-OH and unreacted amino groups. After coupling, the resin was rinsed with DMF (10 x 3 cm³) before N^α-Fmoc deprotection and washing as described above. Then N^αFmoc-L-Ala-OPfp (140 mg, 0.3 mmol) and Dhbt-OH (8.8 mg, 0.054 mmol) was added and after 2 h the resin was rinsed.

15 deprotected and rinsed as above. Fmoc-Ser(O-Ac₃-α-L-Fuc)-OH (93.2 mg, 0.14 mmol), TBTU (43 mg, 0.13 mmol) and N-ethylmorpholine (36 mm³, 0.26 mmol) was dissolved in DMF (2.5 cm³) and after 15 min added to the resin. After 20 h the resin was rinsed with DMF, deprotected and rinsed as described above. After acetylation with 10% acetic anhydride in DMF for 30 min peptide-resin was rinsed with DMF (15 x 3 cm³) and

20 dichloromethane (5 x 3 cm³) and lyophilized before cleavage of the peptide from the solid support with TFA/water to yield crude glycopeptide. The cleavage from the resin was performed with TFA/water (10/1, 22 cm³, 1.3 h, ambient temperature (essentially 1 major peak (80%) and 1 minor peak (20%) in HPLC, longer reaction time gave more by-products)) and after filtration, washing with 90% TFA, evaporation and several triturations with

25 diethylether, the precipitated crude glycopeptide, tri-O-acetate (60 mg) was purified by preparative HPLC using 10 cm³ min⁻¹ 0% solvent B for 20 min, followed by a linear gradient of 10-50% solvent B during 100 min (retention time 90 min). The yield of Ac-Ser(Ac₃-α-L-Fuc)-Ala-Asp-NH₂ after HPLC was 20.7 mg (64%) (¹H NMR data are presented in table 1) and 4 mg (12%) of the compound lacking N^α-acetylation according to

30 NMR. The β-linked compound, Ac-Ser(O-Ac₃-β-L-Fuc)-Ala-Asp-NH₂ was prepared in a similar way on 398 mg of resin with a yield of 28.4 mg (85%) (¹H NMR data are presented

- in table 1) after preparative HPLC (eluting as a single peak in the analytical HPLC of the crude product). The purified acetylated glycopeptide, Ac-Ser(Ac₃-α-L-Fuc)-Ala-Asp-NH₂ was dissolved in dry methanol (1 mg cm⁻³) and sodium methoxide in methanol (1 mol dm⁻³) was added until a wetted pH-paper indicated pH 11. The mixture was stirred at ambient
- 5 temperature for 45 h following the reaction by HPLC, then neutralized with small pieces of solid CO₂ and concentrated. The residue was dissolved in water (1 mg cm⁻³) and purified by preparative HPLC using 10 cm³ min⁻¹ 0% solvent B for 15 min, followed by a linear gradient of 0-20% solvent B during 50 min and then 100% solvent B (retention time 20 min). The yield of Ac-Ser(α-L-Fuc)-Ala-Asp-NH₂ after HPLC was 14.1 mg (87%, single
- 10 peak). Deacetylation of Ac-Ser(Ac₃-β-L-Fuc)-Ala-Asp-NH₂ with sodium methoxide as described above, followed by purification by preparative HPLC using the same gradient yielded 21.8 mg (97%, single peak at 30 min). ¹H NMR data are presented in Table 1.

Table 1

5 ¹H-NMR chemical shifts (ppm) and coupling constants (Hz) of glyco-tripeptides, measured at 500 MHz or 600 MHz at 300 K. Reference: TMS (in d₆DMSO) or internal acetic acid at 2.03 ppm.

| | | Ac-Ser(Ac ₁ -α-L-Fuc)- Ala-Asp-NH ₂ ^a | Ac-Ser(Ac ₁ -β-L-Fuc)- Ala-Asp-NH ₂ ^a | Ac-Ser(α-L-Fuc)- Ala-Asp-NH ₂ ^b | Ac-Ser(β-L-Fuc)- Ala-Asp-NH ₂ ^b |
|----|-----------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|
| 10 | Asp ³ NH ¹ | 7.08 | 7.05 | 7.053 | 7.066 |
| | NH ¹ | 7.12 | 7.12 | 7.372 | 7.327 |
| | N ^a H | 8.03 (6) | 7.96 (6) | 8.105 (8.1) | 8.070 (8.0) |
| | α | 4.14 | 4.01 | 4.723 | 4.743 |
| 15 | β | 2.52 (7:15) | 3.911 (7:15) | 2.855 (7.8:16.8) | 2.869 (7.6:17.0) |
| | β' | 2.67 (5) | 2.67 (5) | 2.948 (5.4) | 2.951 (5.4) |
| | Ala ² N ^a H | 8.15 (6) | 8.21 (6) | 8.215 (6.3) | 8.270 (6.0) |
| | α | 4.20 | 4.16 | 4.418 | 4.377 |
| | β | 1.23 (7) | 1.21 (7) | 1.380 (7.5) | 1.394 (7.2) |
| 20 | Ser ¹ N ^a H | 8.15 (5) | 8.21 (6) | 8.530 (7.2) | 8.288 (6.6) |
| | α | 4.50 | 4.45 | 4.580 | 4.538 |
| | β | 3.68 (8) | 3.58 (8:10) | 3.670 (3.8:10.0) | 4.040 (4.4:16) |
| | β' | 3.68 (4) | 3.93 (4) | 4.076 (3.6) | 4.070 (3.0) |
| | Fuc H-1 | 5.10 (4) | 4.62 (8) | 4.885 (2.6) | 4.377 (7.8) |
| 25 | H-2 | 4.92 (9.8) | 4.87 (9.6) | 3.858 (-) | 3.547 (9.6) |
| | H-3 | 5.15 (-) | 5.04 (4) | 3.810 (-) | 3.662 (3.2) |
| | H-4 | 5.15 (-) | 5.10 (-) | 3.798 | 3.762 |
| | H-5 | 4.42 (6.5) | 4.43 (6.5) | 3.880 (6.9) | 3.762 (6.9) |
| | H-6 | 1.05 | 1.08 | 1.208 | 1.282 |
| 30 | O-Ac | 1.88 | 1.86 | | |
| | O-Ac | 1.92 | 1.91 | | |
| | O-Ac | 2.12 | 2.12 | | |
| | N-Ac | 2.03 | 1.99 | 2.083 | 2.070 |

35

^a2 mg in d₆DMSO (600 mm³)^b2 mg in 10% DC₃COOD/H₂O (600 mm³, pH 2.5)

V. Synthesis and Analysis of Additional Peptides

The methods of Examples I-IV were utilized to synthesize and analyze the following compounds:

- 5 Ac-Ser(α -L-Fuc)-Phe-Asp-NH₂
 Ac-Ser(α -L-Fuc)-Ser-Asp-NH₂
 Ac-Ser(α -L-Fuc)-Asn-Asp-NH₂
 Ac-Ser(α -L-Fuc)-Asp-Asp-NH₂
 Ac-Ser(α -L-Fuc)-Leu-Asp-NH₂
 10 Ac-Ser(α -L-Fuc)-Gly-Asp-NH₂
 Ac-Ser(α -L-Fuc)-Pro-Asp-NH₂
 Ac-Ser-Arg-Asp-NH₂
 Ac-Ser-Phe-Asp-NH₂
 Ac-Ser-Asn-Asp-NH₂
 15 Ac-Ser-Ser-Asp-NH₂
 Ac-Ser(β -L-Fuc)-Arg-Asp-NH₂
 Ac-Ser(α -L-Fuc)-Arg-Asp-NH₂
 Ac-Ser(β -L-Fuc)-Phe-Asp-NH₂
 Ac-Ser(β -L-Fuc)-Ser-Asp-NH₂
 20 Ac-Ser(β -L-Fuc)-Asn-Asp-NH₂
 Ac-Ser(β -L-Fuc)-Asp-Asp-NH₂
 Ac-Ser(β -L-Fuc)-Leu-Asp-NH₂
 Ac-Ser(β -L-Fuc)-Gly-Asp-NH₂
 Ac-Ser(β -L-Fuc)-Pro-Asp-NH₂

25

NMR spectra for the above compounds are presented in Figures 9A-B, 10A-B, 11A-B and 12-31.

VI. Inhibition assays

- 30 Competitive inhibition assays were performed to determine the ability of various glycopeptides to inhibit the binding of selectins to 2,3-sLex glycolipid. An ELISA assay consisting of evaporating 2,3 sLex glycolipid, at 25 picomoles per well,

onto microtiter wells, and then washing the excess off with water was used. The wells were blocked with 5% BSA at room temperature for an hour and then washed with PBS containing 1 mM calcium ion. While the plate was blocked, biotin labelled goat F(ab')₂ IgG (Fc specific) and streptavidin-alkaline phosphatase diluted 1:1500 in 1% BSA-PBS (1 mM calcium ion) were combined with the L-Selectin-IgG chimera (L91-10) at 200 ng/mL and incubated at 37_ C for 15 minutes to allow a complex to form. This provides a soluble "multivalent" receptor. The potential inhibitors are added to the soluble receptor and allowed to react at 37_ C for 45 minutes. It is assumed that the optimal binding of soluble phase receptor/ligand occurs within this time frame. The solutions are then placed in the microtiter wells that have been washed after being blocked. The plates are then incubated at 37_ C for 45 minutes to allow the soluble receptor to bind to the known natural ligand. The positive control is the signal produced by soluble "multivalent" receptor reacted with only the ligand evaporated to the microtiter well. This is considered "100 % binding." The signal produced by receptor previously reacted with inhibitor is divided by the signal produced by the positive control, multiplied by 100, to calculate % receptor bound in the presence of the inhibitor. The reciprocal of this is % inhibition.

Results of the competitive inhibition assays are shown in Figures 5-8. The results demonstrate that the various glycopeptides synthesized inhibit the binding of the L, P and E-selectins differentially and specifically in a concentration dependent manner. Figure 4 is a diagram of the compounds used in the competitive inhibition assays of Figures 5 and 6. The glycopeptide names and corresponding identification letters are found in Table 2 below.

Table 2

| Identification Letter | Compound |
|-----------------------|--------------------------------------------------|
| A | Ac-Ser(α -L-Fuc)-Ala-Asp-NH ₂ |
| B | Ac-Ser(β -L-Fuc)-Ala-Asp-NH ₂ |
| C | Ac-Ser-Phe-Asp-NH ₂ |
| D | Ac-Ser-Asu-Asp-NH ₂ |
| E | Ac-Ser(α -L-Fuc)-Gly-Asp-NH ₂ |
| F | Ac-Ser-Ser-Asp-NH ₂ |
| G | Ac-Ser(β -L-Fuc)-Arg-Asp-NH ₂ |
| H | Ac-Ser(α -L-Fuc)-Arg-Asp-NH ₂ |

Figure 5 demonstrates the differential effects of compounds A and B on the inhibition of binding of L-, P- and E-selection to 2,3 sLex. Both compounds A and B have little effect on the binding of E-selectin to 2,3 sLex glycolipid.

Ac-Ser(α -L-Fuc)-Ala-Asp-NH₂ inhibits the binding of L-selectin to 2,3 sLex at 2 and 4 mm to a greater extent than does Ac-Ser(β -L-Fuc)-Ala-Asp-NH₂

Figure 7 illustrates the differential effects of different concentrations of compounds C, D, E, F and G on the binding of P selectin to 2,3 sLex glycolipid.

Figure 8 illustrates the differential effects of different concentrations of compounds C, D, E, F and H on the binding of L-selectin to 2,3 sLex glycolipid.

VII. Synthesis of selectin binding inhibitors.

A peptide derivative containing a fucose residue is prepared to mimic the binding of SLex to selectin binding sites (Figure 3). Such a structure takes advantage of the interaction between selectin binding sites and the side chain carboxylic acid of aspartic acid, glutamic acid or the C-terminal amino acid present in all blocked peptides. The size of the SLex molecule suggests that peptide scaffolding could place a carboxy of a tripeptide on top that of the sialic acid and the OH group of a

serine residue in a location similar to that of O-1 of the fucose residue. The glyco-peptide scaffolding is designed to interact favorably with the selectin binding site and under appropriate conditions, bind even tighter than the SLex molecule thereby acting as an inhibitor.

5

Additional Examples

In a similar manner as shown in Example VII, other peptide derivatives containing (multiple) carbohydrate residues are prepared to mimic the binding of SLex to selectin binding sites. Carbohydrate residues include mannose, glucose, N-acetylglucosamine, N-acetylgalactosamine, galactose and sialic acid.

10


In one embodiment the bio-oligomer is a glycopeptide. In another embodiment, the bio-oligomer is a glyco-oligonucleotide, in particular glyco-DNA or glyco-RNA. In yet a further embodiment, the bio-oligomer is a chimeric glyco-peptide/glyco-oligonucleotide.

15

The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. Indeed, various modifications of the above-described modes for carrying out the invention which are obvious to those skilled in the art are intended to be within the scope of the following claims.

Claims

1. A glyco-peptide having the structure:



wherein A is an amino acid;

wherein R is a carbohydrate;

wherein X_2-X_{11} is omitted or is an amino acid or a peptidomimetic;

wherein X_1 is a hydrogen, an acetyl, acyl group or a peptide;

wherein X_{12} is an -OH, -NH₂ or a peptide.

2. The glycopeptide of Claim 1

wherein A is selected from the group consisting of serine, threonine, tyrosine, hydroxyproline, asparagine, glutamine, homoserine and hydroxylysine;

wherein R is selected from the group consisting of fucose, glucose, N-acetylglucosamine, galactose, N-acetylgalactosamine and sialic acid;

wherein X_1-X_{12} are omitted or are amino acids selected from the group

consisting of glycine, L-amino acids, D-amino acids, non-genetically encoded amino acids and peptidomimetics; and

wherein X_2 to X_6 and X_8 to X_{12} are omitted; or

wherein X_2 to X_6 and X_9 to X_{12} are omitted; or

wherein X_2 to X_6 and X_{10} to X_{12} are omitted.

3. The glyco-peptide of Claim 2 wherein A is serine, R is O-glycosidically

linked to said serine and X_7 to X_9 are selected from the group consisting of L or D

alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid,

glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline,

serine, threonine, tryptophan, tyrosine, valine, hydroxyproline and hydroxylysine.

4. The glyco-peptide of Claim 3 wherein X₁ is an acetyl group and serine is O-glycosidically linked to R.

5. The glyco-peptide of Claim 3 wherein R is fucose.

5

6. The glyco-peptide of Claim 5 wherein the fucose is selected from the group consisting of α -D-or α -L-fucose and β -D- or β -L-fucose.

7. The glyco-peptide of Claim 3 in which the glyco-peptide is selected from
10 the group consisting of:

Ac-Ser(α -L-Fuc)-Asp-Asp-NH₂,
Ac-Ser(α -L-Fuc)-Ser-Asp-NH₂,
Ac-Ser(α -L-Fuc)-Phe-Asp-NH₂,
Ac-Ser(α -L-Fuc)-Asn-Asp-NH₂,
15 Ac-Ser(α -L-Fuc)-Leu-Asp-NH₂,
Ac-Ser(α -L-Fuc)-Pro-Asp-NH₂,
Ac-Ser(β -L-Fuc)-Gly-Asp-NH₂,
Ac-Ser(β -L-Fuc)-Asp-Asp-NH₂,
Ac-Ser(β -L-Fuc)-Leu-Asp-NH₂,
20 Ac-Ser(β -L-Fuc)-Asn-Asp-NH₂,
Ac-Ser(α -L-Fuc)-Ala-Asp-NH₂,
Ac-Ser(β -L-Fuc)-Ala-Asp-NH₂,
Ac-Ser(β -L-Fuc)-Ser-Asp-NH₂,
Ac-Ser(β -L-Fuc)-Pro-Asp-NH₂,
25 Ac-Ser(α -L-Fuc)-Arg-Asp-OH,
Ac-Ser(α -L-Fuc)-Phe-Asp-OH,
Ac-Ser(α -L-Fuc)-Ser-Asp-OH,
Ac-Ser(α -L-Fuc)-Asn-Asp-OH,
Ac-Ser(α -L-Fuc)-Asp-Asp-OH,
30 Ac-Ser(α -L-Fuc)-Leu-Asp-OH,
Ac-Ser(α -L-Fuc)-Gly-Asp-OH,

Ac-Ser(α -L-Fuc)-Pro-Asp-OH,
Ac-Ser(β -L-Fuc)-Arg-Asp-OH,
Ac-Ser(β -L-Fuc)-Phe-Asp-OH,
Ac-Ser(β -L-Fuc)-Ser-Asp-OH,
5 Ac-Ser(β -L-Fuc)-Asn-Asp-OH,
Ac-Ser(β -L-Fuc)-Asp-Asp-OH,
Ac-Ser(β -L-Fuc)-Leu-Asp-OH,
Ac-Ser(β -L-Fuc)-Gly-Asp-OH,
Ac-Ser(β -L-Fuc)-Pro-Asp-OH,
10 Ac-Ser(α -L-Fuc)-Arg-Gly-OH,
Ac-Ser(α -L-Fuc)-Phe-Gly-OH,
Ac-Ser(α -L-Fuc)-Ser-Gly-OH,
Ac-Ser(α -L-Fuc)-Asn-Gly-OH,
Ac-Ser(α -L-Fuc)-Asp-Gly-OH,
15 Ac-Ser(α -L-Fuc)-Leu-Gly-OH,
Ac-Ser(α -L-Fuc)-Gly-Gly-OH,
Ac-Ser(α -L-Fuc)-Pro-Gly-OH,
Ac-Ser(β -L-Fuc)-Arg-Gly-OH,
Ac-Ser(β -L-Fuc)-Phe-Gly-OH,
20 Ac-Ser(β -L-Fuc)-Ser-Gly-OH,
Ac-Ser(β -L-Fuc)-Asn-Gly-OH,
Ac-Ser(β -L-Fuc)-Asp-Gly-OH,
Ac-Ser(β -L-Fuc)-Leu-Gly-OH,
Ac-Ser(β -L-Fuc)-Gly-Gly-OH,
25 Ac-Ser(β -L-Fuc)-Pro-Gly-OH,
Ac-Ser(α -L-Fuc)-Arg-Glu-NH₂,
Ac-Ser(α -L-Fuc)-Phe-Glu-NH₂,
Ac-Ser(α -L-Fuc)-Ser-Glu-NH₂,
Ac-Ser(α -L-Fuc)-Asn-Glu-NH₂,
30 Ac-Ser(α -L-Fuc)-Asp-Glu-NH₂,
Ac-Ser(α -L-Fuc)-Leu-Glu-NH₂,

Ac-Ser(α -L-Fuc)-Gly-Glu-NH₂,
Ac-Ser(α -L-Fuc)-Pro-Glu-NH₂,
Ac-Ser(β -L-Fuc)-Arg-Glu-NH₂,
Ac-Ser(β -L-Fuc)-Phe-Glu-NH₂,
5 Ac-Ser(β -L-Fuc)-Ser-Glu-NH₂,
Ac-Ser(β -L-Fuc)-Asn-Glu-NH₂,
Ac-Ser(β -L-Fuc)-Asp-Glu-NH₂,
Ac-Ser(β -L-Fuc)-Leu-Glu-NH₂,
Ac-Ser(β -L-Fuc)-Gly-Glu-NH₂, and
10 Ac-Ser(β -L-Fuc)-Pro-Glu-NH₂.

8. A glycopeptide according to Claim 1
wherein A is selected from the group consisting of serine, threonine, tyrosine,
hydroxyproline, asparagine, glutamine, homoserine and hydroxylysine;
15 wherein R is selected from the group consisting of fucose, glucose,
N-acetylglucosamine, galactose, N-acetylgalactosamine and sialic acid;
wherein X₁-X₁₂ are omitted or are amino acids selected from the group
consisting of glycine, L-amino acids, D-amino acids, non-genetically encoded amino
acids and peptidomimetics; and
20 wherein X₃ to X₄ and X₂ to X₁₁ are omitted;
wherein X₃ to X₅ and X₂ to X₁₁ are omitted; or
wherein X₃ to X₈ and X₂ to X₁₁ are omitted.

9. The glyco-peptide of Claim 8 wherein A is serine;
25 wherein R is O-glycosidically linked to said serine;
wherein X₁ to X₁₂ are selected from the group consisting of L- or D-alanine,
arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine,
histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine,
threonine, tryptophan, tyrosine, valine, hydroxylysine and hydroxyproline;
30 wherein X₂ is selected from the group consisting of aspartic acid and glutamic
acid and X₁ is a hydrogen, acetyl or acyl group.

10. The glyco-peptide of Claim 8 wherein R is fucose.
11. The glyco-peptide of Claim 10 wherein the fucose is selected from the group consisting of α -L-or α -D-fucose and β -L- or β -D-fucose.
- 5 12. The glyco-peptide of Claim 1 in which X_{12} is attached to a solid phase support.
13. A method for identifying a glyco-peptide ligand for an acceptor molecule
10 consisting of the steps of:
- (a) generating the glyco-peptide of Claim 1;
 - (b) introducing to said glyco-peptide an acceptor molecule of interest such that said acceptor molecule will recognize and bind to said glyco-peptide; and
 - (c) isolating said glyco-peptide that exhibits binding with the acceptor
15 molecule.
14. The method of Claim 13 in which the acceptor molecule is selected from the group consisting of antibodies, lectins, receptors, viruses, bacteria, proteins, carbohydrates, nucleic acids, lipids, drugs, metals and small molecules.
- 20 15. The method according to Claim 14 in which the acceptor molecule is a protein.
16. The method according to Claim 15 in which the acceptor molecule is a
25 selectin.

structur s.

21. The method according to Claims 17 or 20 in which the detection of step (c) is of a biological activity selected from the group consisting of cytotoxicity, anti-tumor activity, anti-bacterial activity, anti-fungal activity, anti-viral activity, anti-parasite activity, growth factor activity, growth inhibitor activity, hormone activity, neurotransmitter activity, immunomodulator activity, and anti-cell adhesion activity.
22. An anti-cell adhesion molecule consisting of a glyco-peptide sequence determined according to the method of Claims 13, 17 or 20.
23. A therapeutic agent consisting of a glyco-peptide sequence determined according to the method of Claims 13, 17 or 20.
24. A cytotoxic molecule consisting of a glyco-peptide sequence determined according to the method of Claims 13, 17 or 20.
25. An anti-tumor molecule consisting of a glyco-peptide sequence determined according to the method of Claims 13, 17 or 20.
26. An anti-microbial molecule consisting of a glyco-peptide sequence identified according to the method of Claims 13, 17 or 20.
27. A growth factor agonist consisting of a glyco-peptide sequence identified according to the method of Claims 13, 17 or 20.
28. A growth factor antagonist consisting of a glyco-peptide sequence determined according to the method of Claims 13, 17 or 20.
29. A hormone agonist consisting of a glyco-peptide sequence determined according to the method of Claims 13, 17 or 20.

17. A method for identifying a biologically active glyco-peptide ligand consisting of the steps of:

- (a) generating a glyco-peptide of Claim 12 in which the solid phase support is modified so that a portion of the glyco-peptide can be released;
- 5 (b) releasing a portion of the glyco-peptide from the solid phase support/glyco-peptide combination in situ;
- (c) detecting the biological activity of the released glyco-peptide that exhibits the specific biological activity of interest;
- (d) isolating a solid phase support/glyco-peptide combination that exhibits
10 the specific biological activity of interest; and
- (e) determining the sequence of the glyco-peptide remaining in the solid phase support/glyco-peptide isolated in step (d).

18. The method according to Claim 17 in which the solid phase support is
15 modified so that release of glycopeptide is acid-sensitive, base-sensitive, nucleophilic-sensitive, photosensitive, oxidation-sensitive, or reduction-sensitive.

19. The method according to Claim 17 in which the in situ release of step
20 (b) is affected by enzymatic cleavage, chemical cleavage or a photochemical cleavage.

20. A method for identifying a biologically active glycopeptide ligand consisting of the steps of:

- (a) generating the glycopeptide of Claim 12;
- 25 (b) incubating an acceptor molecule with the solid-phase-bound glycopeptide;
- (c) detecting the interaction between the acceptor molecule and the biologically active glycopeptide by radiolabeling, fluorescence or color detection methods or by direct visual detection of aggregation;
- 30 (d) labeling the bound acceptor molecule; and
- (e) isolating the active solid-phase particles and determining the ligand

30. A hormone antagonist consisting of a glyco-peptide sequence determined according to the method of Claims 13, 17 or 20.

31. A cytotoxic molecule consisting of a glyco-peptide sequence determined
5 according to the method of Claims 13, 17 or 20.

Synthesis of Fmoc-Ser (Beta-Fuc(Ac3))




FIGURE 1




FIG. 2





FIG. 3






FIG. 4

COMPETITIVE INHIBITION ASSAY--L,E,P--SELECTIN SOLID PHASE LIGAND 2,3 sLex




FIGURE 5

COMPETITIVE INHIBITION ASSAY—E,L,P—SELECTIN

SOLID PHASE LIGAND 2,3 sLex

KB02109328




FIGURE 6

COMPETITIVE INHIBITION ASSAY-P-SELECTIN

SOLID PHASE LIGAND 2,3 sLex

KB06259367




FIGURE 7

COMPETITIVE INHIBITION ASSAY--L-SELECTIN

SOLID PHASE LIGAND 2,3 sLex

KB06229365






FIGURE 8






FIG. 10A






FIG. 10B






FIGURE 12.




FIGURE 13

PC-5a⁺(α -Fuc)-Pen-Rsp-NH₂

41.03.12.R4

MS-10.31.C

01/08/94
 MS-10.31.C
 DATE 2-4-93
 17 180.0 048.137
 18 180.0 048.137
 19 180.0 048.137
 20 180.0 048.137
 21 180.0 048.137
 22 180.0 048.137
 23 180.0 048.137
 24 180.0 048.137
 25 180.0 048.137
 26 180.0 048.137
 27 180.0 048.137
 28 180.0 048.137
 29 180.0 048.137
 30 180.0 048.137
 31 180.0 048.137
 32 180.0 048.137
 33 180.0 048.137
 34 180.0 048.137
 35 180.0 048.137
 36 180.0 048.137
 37 180.0 048.137
 38 180.0 048.137
 39 180.0 048.137
 40 180.0 048.137
 41 180.0 048.137
 42 180.0 048.137
 43 180.0 048.137
 44 180.0 048.137
 45 180.0 048.137
 46 180.0 048.137
 47 180.0 048.137
 48 180.0 048.137
 49 180.0 048.137
 50 180.0 048.137
 51 180.0 048.137
 52 180.0 048.137
 53 180.0 048.137
 54 180.0 048.137
 55 180.0 048.137
 56 180.0 048.137
 57 180.0 048.137
 58 180.0 048.137
 59 180.0 048.137
 60 180.0 048.137
 61 180.0 048.137
 62 180.0 048.137
 63 180.0 048.137
 64 180.0 048.137
 65 180.0 048.137
 66 180.0 048.137
 67 180.0 048.137
 68 180.0 048.137
 69 180.0 048.137
 70 180.0 048.137
 71 180.0 048.137
 72 180.0 048.137
 73 180.0 048.137
 74 180.0 048.137
 75 180.0 048.137
 76 180.0 048.137
 77 180.0 048.137
 78 180.0 048.137
 79 180.0 048.137
 80 180.0 048.137
 81 180.0 048.137
 82 180.0 048.137
 83 180.0 048.137
 84 180.0 048.137
 85 180.0 048.137
 86 180.0 048.137
 87 180.0 048.137
 88 180.0 048.137
 89 180.0 048.137
 90 180.0 048.137
 91 180.0 048.137
 92 180.0 048.137
 93 180.0 048.137
 94 180.0 048.137
 95 180.0 048.137
 96 180.0 048.137
 97 180.0 048.137
 98 180.0 048.137
 99 180.0 048.137
 100 180.0 048.137




FIGURE 14

Ac-Sar(α Fuc)-Asp Asp-NH₂

KL02A12.95
HC-80.844 NAME.18



NAME.011
DATE 1-1-93
BT 008.137
SY 288.0
P1 8408.842
P2 32768
P3 32768
P4 7403.087
P5 7403.087
P6 10.9
P7 10.9
P8 10.9
P9 10.9
P10 10.9
P11 10.9
P12 10.9
P13 10.9
P14 10.9
P15 10.9
P16 10.9
P17 10.9
P18 10.9
P19 10.9
P20 10.9
P21 10.9
P22 10.9
P23 10.9
P24 10.9
P25 10.9
P26 10.9
P27 10.9
P28 10.9
P29 10.9
P30 10.9
P31 10.9
P32 10.9
P33 10.9
P34 10.9
P35 10.9
P36 10.9
P37 10.9
P38 10.9
P39 10.9
P40 10.9
P41 10.9
P42 10.9
P43 10.9
P44 10.9
P45 10.9
P46 10.9
P47 10.9
P48 10.9
P49 10.9
P50 10.9
P51 10.9
P52 10.9
P53 10.9
P54 10.9
P55 10.9
P56 10.9
P57 10.9
P58 10.9
P59 10.9
P60 10.9
P61 10.9
P62 10.9
P63 10.9
P64 10.9
P65 10.9
P66 10.9
P67 10.9
P68 10.9
P69 10.9
P70 10.9
P71 10.9
P72 10.9
P73 10.9
P74 10.9
P75 10.9
P76 10.9
P77 10.9
P78 10.9
P79 10.9
P80 10.9
P81 10.9
P82 10.9
P83 10.9
P84 10.9
P85 10.9
P86 10.9
P87 10.9
P88 10.9
P89 10.9
P90 10.9
P91 10.9
P92 10.9
P93 10.9
P94 10.9
P95 10.9
P96 10.9
P97 10.9
P98 10.9
P99 10.9
P100 10.9




FIGURE 15




FIGURE 17

Ac-Ser (α-Fuc)-Pro-Arg-NH₂

VL03.12.A8
HC.10.30.0



NAME: 011
DATE: 2-4-93
SV: 500.137
Q1: 8000.000
Q2: 32768
T0: 32768
R0: 7482.007
R2/PT: .008
F0: 7.0
F2: 0.0
A0: 2.106
R0: 40
R2: 10
TC: 300
F0: 8400
R2: 8073.800
AP: ETL P0
L0: -.508
R0: -.500
C0: 34.00
C1: 0.0
C2: 0.000
F0: 1.0
F2: 1.0
R2/CH: 130.740
R0/CH: 278
R2: 0000.00




FIGURE 18

XL-23 12.09 6.5m-A-g-RSP-NH₂
MC-10.33.C



MCPEP.816
DATE 28-1-83
ST 508.137
ST 188.0
ST 5008.006
ST 32789
TD 25764
AM 7482.017
MZ/PT 7482.036
PD 7.9
AD 9.9
PD 2.183
PD 22
PD 308
PD 2408.006
PD 2033.006
PD 233.10
LS 8.00
ST 34.00
ST 8.00
ST 8.9004
PD 138.740
PD 138.740
PD 138.740
ST 8008.03




FIGURE 19




FIGURE 21




FIGURE 22

KL03.12.02
AS-SEP-10-12-15-10-10

000000

MID2D.041
DATE 4-3-83
57 100.137
01 100.000
81 227.400
70 227.400
84 742.007
M2/71 .053
PV 7.0
A2 0.0
A8 0.123
R9 0.4
R8 16
TE 300
P8 8400
C3 9033.308
D5 23.70
L8 8.308
R8 8.308
C1 84.00
C1 0.0
C1 0.0019
M2/71 100.007
M2/71 100.007
M2/71 100.007
M2 67.18.13




FIGURE 23




FIGURE 24

Ac.50 (s Fuc).-Am.-Asp.NH₂

ML.03.12.04
HC.10.05.0



NOEPP 003
DATE 31-8-99
EP 504.137
ST 144.0
CI 6000.008
SI 32758
TO 32758
SV 1463.187
ML/PT .455
PW 7.0
RD 9.0
AS 2.180
MS 100
KS 22
TE 306
FV 0440
F2 2033.008
EP 23. PG
LB .200
GB 0.0
CT 34.00
CT 0.0
F1 0.000P
F2 .455P
ML/CM 138.740
PW/CM .078
SA 0008.12




FIGURE 25




FIGURE 28




FIGURE 26

Ac-Ser(ψ-Fuc)-Leu-Asp-NH₂

11.06.12.96

11.06.12.96



NAME: SER
 DATE: 31-5-83
 ST: 100.137
 SI: 100.000
 SI: 100.000
 TD: 100.000
 CM: 100.000
 HZ/PT: 100.000
 PD: 100.000
 AD: 100.000
 AS: 100.000
 TC: 100.000
 FC: 100.000
 CS: 100.000
 DF: 100.000
 LB: 100.000
 CH: 100.000
 CV: 100.000
 FI: 100.000
 HZ/CH: 100.000
 PPM/CH: 100.000
 SN: 100.000




FIGURE 27




FIGURE 30




FIGURE 31

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/11370

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 38/14

US CL : 530/322

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/322

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, CAS Online

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|------------------------------------------------------------------------------------|-----------------------|
| A | US, A, 4,395,399 (OVCHINNIKOV ET AL) 26 July 1983, see entire document. | 1-31 |
| A | US, A, 4,833,092 (GEYSEN) 23 May 1989, see entire document. | 13-21 |
| A | US, A, 5,194,392 (GEYSEN) 16 March 1993, see entire document. | 13-21 |
| A | US, A, 4,386,026 (PONPIPOM ET AL) 31 May 1983, see entire document. | 1-31 |
| A | US, A, 4,719,289 (KOLAR ET AL) 12 January 1988, see entire document. | 1-31 |

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

| | | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| * Special categories of cited documents: | *T | later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention |
| *A* document defining the general state of the art which is not considered to be of particular relevance | *X* | document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone |
| *E* earlier document published on or after the international filing date | *Y* | document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | *A* | document member of the same patent family |
| *O* document referring to an oral disclosure, use, exhibition or other means | | |
| *P* document published prior to the international filing date but later than the priority date claimed | | |

Date of the actual completion of the international search

07 DECEMBER 1994

Date of mailing of the international search report

JAN 25 1995

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

DAVID LUKTON

Telephone No. (703) 308-0196

THIS PAGE BLANK (USPTO)

THIS PAGE BLANK (USPTO)